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Abstract 
Endometrial cancer (EC) is the most common gynaecological cancer in Aotearoa, with 
rates rising rapidly in premenopausal women. There is an increasing number of women 
who are not able to undergo the standard of care which is hysterectomy (removal of the 
uterus). The levonorgestrel intrauterine device (LNG-IUD) is an alternative treatment 
that allows women to retain their uterus. However, around half of women will not 
respond to this treatment and there is no way of predicting response. Predictive 
biomarkers will enable safer and more equitable access to this treatment. Extracellular 
vesicles (EVs) are particles found in bodily fluids enriched with miRNAs and are a 
novel opportunity to identify blood-based biomarkers of LNG-IUD treatment response. 
Two cell line culture models of LNG resistance were used to investigate the expression 
of miRNA biomarkers of EC within EVs. EVs were isolated from cell culture media, 
and their size, concentration and morphology characterised using tunable resistive pulse 
sensing (TRPS), transmission electron microscopy (TEM) and Western blotting. RT-
qPCR was carried out on RNA extracted from EVs, followed by pathway enrichment 
analysis. miRNA expression was validated in EVs from EC patient plasma samples 
from the UOW gynaecological cancer biobank. 
EV size and concentration was similar between resistant and sensitive cells as found by 
TRPS. TEM showed isolated particles had the characteristic EV double membrane. 
Protein analysis through Western blotting (TSG101, CD9 and ApoB) demonstrated EV 
purity. Many candidate miRNA biomarkers were expressed at very low levels in culture 
media EVs, and high biological variation was observed. There were no statistically 
significant differences in expression of any of the miRNAs investigated in media EVs, 
although miR-93, miR-133a and miR-205 were close to significance (p=0.071, 
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p=0.088, p=0.070 respectively). Pathway analysis indicated these miRNAs may be 
providing resistant cells with greater oncogenic potential. The miRNAs were expressed 
at higher levels in EC patient plasma EVs than the media EVs. 
This was the first study to investigate EV biomarkers of LNG-IUD treatment resistance. 
miRNAs currently thought to be involved in EC were expressed in low levels in culture 
media EVs. miR-93, miR-133a and miR-205 warrant further research. This study also 
acted as a proof of concept that miRNAs previously investigated in EC can be detected 
within patient plasma EVs. This study has laid the foundations for further EC EV 
research and has provided valuable preliminary investigations into EC and LNG 
resistance EV miRNA biomarkers. 
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 Introduction 
1.1 Endometrial cancer  
Endometrial cancer (EC) is cancer of the inner lining of the uterus, the endometrium. 
Globally, EC is the most common gynaecological cancer and is one of the few cancers 
with increasing incidence (1, 2). EC was traditionally viewed as a cancer of older, post-
menopausal women, but concerningly incidence is rising in younger women (3). The 
most common symptom is abnormal uterine bleeding including post-menopausal 
bleeding, which leads to most ECs being detected early, with around 75% of patients 
being diagnosed with stage I cancer (4). The prognosis for early stage EC is generally 
good, with a high five-year survival rate of around 95% (5). Standard treatment for EC 
includes a total hysterectomy and bilateral salpingo-oophorectomy (TH-BSO), which 
for pre-menopausal women results in a loss of fertility and early entry into menopause 
(6).  
 Aetiology 
EC is widely regarded as a hormone driven cancer, with an estimated 80% of ECs 
caused by hormone imbalances (7). Oestrogens have a proliferative effect on the 
glandular epithelial cells of the endometrium while progesterone can counteract 
oestrogen-driven endometrial growth, maintaining tissue homeostasis (8). Disruption to 
this careful hormone balance can contribute to the development of endometrial 
hyperplasia (EH) and subsequently EC (9).  
 Risk factors 
Obesity is the primary risk factor for EC, with 40-57% of EC’s attributable to being 
overweight or obese (10, 11). The elevated risk is through increased oestrogen 
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production from high aromatase levels in excess adipose tissue (12), insulin resistance 
and inflammation (13). Additional risk factors include exogenous oestrogen source, 
such as tamoxifen treatment and hormone replacement therapy, while protective factors 
reduce oestrogen exposure and increase progesterone levels, such as oral contraceptive 
use (14-17). Lynch syndrome, characterised by a mutation in one of the mismatch 
repair genes increases lifetime EC risk to 60% (18).  
 Classification 
EC has been traditionally split in to two types, type I EC being hormone dependent and 
type II non-hormone dependent (19). As this dualistic model fails to capture the full 
heterogeneity of EC, this system is no longer used. Currently, ECs are classified on 
stage, grade and histological subtype, with the two most common subtypes being 
endometrioid and serous. Staging evaluates the depth of invasion and extent of disease 
spread using the International Federation of Gynecology and Obstetrics (FIGO) 
classification system (Figure 1), and a grade (1-3) is assigned based on the degree of 
glandular differentiation (20).  
Results from The Cancer Genome Atlas (TCGA) have provided new molecular 
insights, categorising EC into four genomic subtypes each with a different prognostic 
outcome (21). Following this, the Proactive Molecular Risk Classifier for Endometrial 
Cancer (ProMisE) guidelines (22) were developed to provide a more clinically 
accessible method of subtyping EC through assays such as immunohistochemistry 
(IHC). The resulting EC molecular subtypes are DNA polymerase epsilon (POLE) 
mutated, mismatch repair deficient (MMRd), p53 abnormal (p53abn) and non-specified 
molecular profile (NSMP). POLE subtypes have significantly better outcomes than the 
other subtypes, with p53abn having markedly poorer prognosis (22). Thus, molecular 
profiling can provide more accurate prognostic predictions when compared to 
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Figure 1: FIGO staging system for endometrial cancer. FIGO – International Federation 
of Gynecology and Obstetrics. Adapted from Cancer Research UK (23) 
 
traditional classification systems (24). The Post-Operative Radiation Therapy in 
Endometrial Cancer (PORTEC) trials demonstrated that molecular subtyping improves 
risk stratification and allows for more effective treatment prescription (25, 26). 
However, POLE subtypes are only assessable through DNA sequencing, preventing 
widespread implementation of molecular classification. In the future, EC patients will 
be benefit from incorporating genetic information to provide personalised cancer care. 
Currently, in Aotearoa testing for MMRd through IHC is part of clinical practice, but 
tests for p53 and POLE subtypes are not routinely carried out.  
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 Treatment 
Standard of care for EC is TH-BSO (6). Pre-surgical tests such as pipelle biopsy or 
pelvic MRI can help determine whether the cancer is limited to the uterus, and lymph 
node assessment is carried out on cancers stage II or higher to identify patients 
requiring adjuvant therapy (27). After hysterectomy, histological evaluation of the 
tissue is carried out to stage and grade the tumour and any further treatment required is 
administered. For low-grade early EC, surgery alone gives a 5-year survival rate of over 
90% (28). Adjuvant therapy for later stage, higher grade ECs can include radiation, 
either external beam radiation therapy (EBRT) or vaginal brachytherapy, and 
chemotherapy (5).  
 Conservative treatment of EC 
For some women, hysterectomy is not a suitable option and they require conservative 
treatment for EC. This includes women who wish to retain their fertility, as well as 
women who are medically inoperable or high-risk for surgery. This is fairly common, 
with international data suggesting around 10% of EC patients are medically inoperable, 
and 12% of EC patients are under 50 years old (29, 30). Currently, there is no data on 
the number of EC patients in Aotearoa receiving conservative treatment. Only low-risk 
early ECs (Stage 1A Grade 1 endometrioid cancers) are eligible for fertility-preserving 
treatment, and patients must also be advised that this is a non-standard treatment and 
counselled of the risks (27).  
Conservative treatment for early EC involves progestin treatment, often the oral 
progestins medroxyprogesterone acetate (MPA) or megestrol acetate (MA), which 
appear to counteract the proliferative effect of oestrogens. Oral progestins can 
successfully treat early EC with response rates of between 70-80% (31, 32), and no 
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difference in survival between surgical and progestin therapies for Stage IA EC (33). 
However, recurrence rates (RR) are around 30-40% (34), likely due to downregulation 
of progesterone receptor (PR) during treatment resulting in desensitisation to progestin 
(35). Because of this, patients undergo routine surveillance with endometrial biopsies 
every three to six months (36). In medically operable women, prophylactic 
hysterectomy is often performed following treatment once childbearing is complete 
even if complete response is observed (37). While progestin treatment is an appealing 
alternative for many women, our inability to predict who will respond increases the risk 
of prescribing this treatment.  
 
1.2 LNG-IUD treatment  
The levonorgestrel intrauterine device (LNG-IUD) is a local hormone therapy that has 
recently been explored as an alternative progestin treatment for EH and early EC, 
working by delivering a synthetic form of progesterone directly to the uterine cavity.  
The efficacy of the LNG-IUD has been assessed largely through retrospective studies 
(38, 39), with only three prospective studies carried out thus far. The complete response 
(CR) rates varied between these studies, with the observed CRs being 37% (40), 54% 
(41) and 43% (42). The variation in rate may be due to when response was assessed, 
and the study with assessment after 12 months found the highest CR rate. Optimum 
treatment duration has only been recently evaluated in one study, which recommended 
a 15-month treatment period (43). Thus, extending treatment duration in future trials 
may see an improved CR. The small cohorts of less than forty in these trials limit the 
ability to effectively evaluate this treatment. Through larger cohorts, ongoing clinical 
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trials aim to provide more robust evidence that supports clinical use of the LNG-IUD as 
a conservative treatment for early EC (NCT02397083, NCT02035787, NCT03463252).   
Multiple meta-analyses have demonstrated that the LNG-IUD is more effective than 
oral progestins in treating EH (44-46). The ability to determine whether LNG-IUD is 
also more efficacious in treating early EC is hindered by the limited number of studies 
carried out to date. A meta-analysis found no difference in CR or RR between the two 
treatments, but with only two studies in the analysis this result must be interpreted with 
caution (47).  
Efficacy aside, the LNG-IUD may be superior to oral progestins in other areas. The 
LNG-IUD can be used for up to five years to provide continuing protection (48), with 
most women opting to keep their LNG-IUD for this reason (49). As a systemic 
hormonal therapy, oral progestins have associated side effect such as headaches and 
weight gain, resulting in lower satisfaction, reduced patient compliance and increased 
withdrawal from treatment (48, 50-52). Similar results have been found comparing 
LNG-IUD and oral progestin treatment in other gynaecological conditions (53-55). The 
high compliance observed with LNG-IUD suggests this may be a promising alternative 
to oral progestins, yet the frequent and invasive testing required for ongoing 
surveillance reduces the accessibility of LNG-IUD treatment.  
 
1.3 LNG-IUD response biomarkers 
Biomarkers are a measurable indicator of biological condition present in tissue or 
bodily fluid that is reflective of a state of health or disease. Biomarkers can be involved 
in disease diagnostics, evaluating prognosis and assessing treatment response (56) and 
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are commonly based on DNA mutations, gene expression (mRNA, miRNA or lncRNA 
levels) or protein expression.  
The risk of recurrence and inability to predict which patients will recur prevents the 
LNG-IUD becoming a standard treatment for women with early EC who wish to 
preserve their fertility or are medically inoperable. Opting for conservative treatment is 
currently a risk as this may result in tumour progression and a more unfavourable 
prognosis. Therefore, biomarkers of LNG-IUD response could greatly improve patient 
care by identifying patients who are good candidates for conservative treatment with 
the LNG-IUD (57). While calls for validation of candidate biomarkers is growing (57-
59), there are still currently no clinically available predictive biomarkers of LNG-IUD 
treatment response (60). 
  Clinical features as predictors of progestin treatment 
response  
Pre-treatment clinical features such as age, body mass index (BMI) and uterine 
diameter have been investigated as predictors of response to progestin treatment, 
usually with no significant association found (38, 41, 61, 62). Studies frequently show a 
conflict, for example a high BMI has been associated with both resistance (61) and 
response to treatment (62), meanwhile other studies have found no association (38, 63). 
Overall, as concluded in two recent biomarker reviews (58, 60), conflicting and non-
significant results suggest that clinical features show little potential in predicting LNG-
IUD treatment response.  
  Molecular biomarkers of progestin treatment response  
Research investigating biomarkers of LNG-IUD response is currently limited, with 
more studies focusing on response to oral progestin treatment. PR and oestrogen 
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receptor (ER) expression are the most widely studied biomarkers of progestin treatment 
response. A meta-analysis found that PR and ER are predictive of LNG-IUD response, 
however the low specificity (0.5) and sensitivity (0.81) meant the predictive ability was 
inadequate for clinical use (64). Therefore, current recommendations discourage the use 
of PR expression when evaluating patient candidacy for progestin treatment (65).  
Most studies utilise clinical samples such as endometrial biopsies and IHC to 
investigate candidate genes as biomarkers based on biological relevance to EC and/or 
PR (66). Many of the studies taking this approach have not found any significantly 
associated genes (41, 67). Meanwhile, the limited successes have not translated into a 
biomarker that is being used clinically (68).  
The small cohort sizes limit the ability to validate candidate biomarkers, impeding the 
progression to their clinical use in EC treatment (69). Large scale clinical trials are hard 
to achieve as the LNG-IUD is not a widely used EC treatment, and within the cohort an 
even smaller proportion are non-responders. The retrospective nature of many 
biomarker discovery studies can introduce bias due to missing relevant clinical 
information, and due to differences in storage and processing procedures in multicentre 
studies (70). Many ongoing clinical trials have included molecular biomarker testing as 
part of their study design (NCT02990728, NCT02397083), and large, prospective 
cohorts may provide more robust evaluation of candidate biomarkers. However, a 
limitation of these trials is their focus on longstanding biomarkers such as PR and ER 
which have already been extensively investigated, with inconclusive results. A novel 
approach may be required to present new candidate molecular biomarkers of LNG-IUD 
treatment resistance for evaluation.  
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1.4 Extracellular vesicles as cancer biomarkers  
There has been increasing interest in the role of extracellular vesicles (EVs) as cancer 
biomarkers, due to their unique properties and role in cancer progression (71-73). EVs 
are membrane-bound particles that cannot replicate and are actively released from most 
cell types. EV is a general term used to describe a range of particles which differ by 
biogenesis (74), with three classical subtypes: exosomes, microvesicles and apoptotic 
bodies (Figure 2). To maintain consistency in the literature, use of the term EV is 
recommended unless the specific biogenic origins of the vesicle can be demonstrated 
(74).  
 
Figure 2: The biogenesis of the three classical subtypes of extracellular vesicles: 
exosomes, microvesicles and apoptotic bodies. Exosomes are intraluminal vesicles 
(ILVs) that have formed through the invagination of the endosomal membrane and 
released in the extracellular space following fusion of the multivesicular body (MVB) 
and plasma membrane. Microvesicles are formed by outward budding of the plasma 
membrane. Apoptotic bodies are released by dying cells through blebbing of the plasma 
membrane. Made using BioRender.  
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EV cargo includes molecules such as DNA, proteins and various RNA species. The 
transfer of molecular messengers from EVs are a critical form of cell communication 
that can alter the phenotype of the recipient cell. Tumour and microenvironment cells 
secrete EVs which can cause immune response suppression, angiogenesis induction, 
establishment of the metastatic niche, and enhanced growth and metastatic ability of 
nearby cells (75, 76). EV contents are reflective of the cell of origin providing insight 
into the physiological state of the tissue. The cargo is protected by the lipid bilayer 
which provides a stable environment, preventing RNA degradation and allowing the 
content to be studied even after long term storage and freeze-thaw cycles (77, 78). 
EVs are abundant in bodily fluid making them prime candidates for use in liquid 
biopsy, having been successfully isolated from blood, urine and saliva (79-81). Liquid 
biopsies facilitate non-invasive testing which is useful when accessing tumour material 
is challenging, while also providing access to novel circulating biomarkers that may 
differ from those within tissue. EV biomarkers may be able to diagnose and monitor 
disease progression at earlier stages than conventional imaging (82), and detect 
mutations that will give resistance to treatment (83). The acidic and hypoxic tumour 
microenvironment increases EV secretion resulting in elevated levels of EVs in bodily 
fluids (84), providing more tumour material for analysis (85). Other rarer blood-based 
biomarker sources such as circulating tumour cells (CTCs) or circulating tumour DNA 
(ctDNA) may not be detectable through a typical blood draw, particularly if the cancer 
is early stage (86, 87) highlighting the unique value of EV biomarkers in liquid biopsies 
for early cancer diagnosis and management.  
 EV isolation  
There are a wide range of methods available to isolate EVs from biofluids, each with 
advantages and limitations that make them practical for different purposes (Table 1). 
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Choosing an isolation method for biomarker research is challenging, as a balance 
between purity, efficiency and yield must be found. There is currently no 
standardisation of isolation methodology, thus it is critical for all EV studies to adhere 
to the Minimal Information for Studies of Extracellular Vesicles (MISEV) guidelines 
(74) and provide detailed methodologies to maximise reproducibility.  
Table 1: Comparison of EV isolation methods. Adapted from Sidhom et al. (88) 



















Specificity  ++ + ++ + +++ +++ 
EV yield ++ +++ +++ +++ ++ + 




++ ++ + + ++ + 
Time +++ +++ + ++ +++ ++ 
Cost + ++ + + +++ +++ 
Efficiency  ++ ++ +++ ++ ++ +++ 
Scalability  ++ ++ +++ +++ + + 
Scale for comparison of each factor: + (low), ++ (intermediate), +++ (high) 
dUC: differential ultracentrifugation, UF: ultrafiltration, SEC: size exclusion chromatography, PEG: polyethylene 
glycol-based precipitation, IA: immunoaffinity capture, MF: microfluidics, EV: extracellular vesicle 
 
 EV characterisation  
EV characterisation is required to demonstrate that experimental outcomes can be 
correctly attributed to EVs. The MISEV guidelines (74) provide four main 
recommendations for characterising EVs, the EV source and preparation should be: 
described quantitively, characterised to determine EV abundance and demonstrate 
intact vesicles, tested for EV-associated components, and tested for co-isolated non-EV 
contaminants. With current technologies, no single approach can characterise the full 
spectrum of EV properties and a range of methods must be employed to sufficiently 
characterise EVs (89). Like isolation methodologies, each characterisation method has 
its own strengths and weaknesses (Table 2). 
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Table 2: Capabilities of common EV characterisation methodologies. Adapted from 


















– Bulk ++ +++ +++ – N 
Immunoblotting – Bulk + + + – Y 
Immunosorbent 
assays 
– Bulk + +++ + – Y 
Physical analysis 
Direct imaging 
EM >5nm Individual + + + +++ Y 
AFM >5nm Individual + + + ++ N 
Indirect optical detection 
DLS 5-2000nm Bulk ++ +++ +++ ++ Y 
NTA 50-1000nm Individual ++ ++ ++ ++ Y/N 
Flow cytometry 
– scattering 
>300nm Individual ++ +++ ++ + N 
Flow cytometry 
– fluorescence 
>100nm Individual +++ ++ ++ + Y 
Indirect non-optical detection 
TRPS >30nm Individual +++ + ++ ++ N 
Performance: + poor, ++ intermediate, +++ high 
AFM: atomic force microscopy, DLS: dynamic light scattering, EM: electron microscopy, NTA: nanoparticle tracking analysis, 
TRPS: tunable resistive pulse sensing 
 
1.5 EVs in EC research 
The use of EVs as biomarkers in EC is in its infancy, with limited studies conducted to 
date (Table 3). Mostly diagnostic biomarkers have been focused on, with only a few 
studies investigating prognostic biomarkers (90-92). Candidate biomarkers identified 
thus far require validation and further research into their potential.  
miRNAs have been a focus of many EV EC studies thus far. miRNAs are short, single 
stranded RNA molecules that act as post-transcriptional regulators of gene expression 
through binding to mRNA molecules with complementary sequences, preventing 
translation into protein. Interest in miRNAs is largely due to their ability to modify 
proliferative and metastatic pathways contributing to EC development (93). miRNAs 
are selectively packaged into EVs, leading to differing miRNA expression profiles 
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Table 3: Endometrial cancer studies investigating EVs as biomarkers 













Urine (PEG) miRNAs Differing performance of miRNAs 
in urine supernatant vs EVs. miR-
21 upregulated and miR-106b 




al. (2018) (95) 
EC n=22 
HC n=5 
Urine (UC) miRNAs miR-200c, miR-23b and miR-100   









Plasma (UC) N/A Elevated EV concentration in blood 
of EC vs HC  
Diagnostic 
biomarkers 
Xu et al. 




Serum (PEG)  circRNAs Identified DE circRNAs using RNA 
seq. Validated expression of 
hsa_circ_0109046 and 











miRNAs Identified 114 DE miRNAs 
between EC and HC 
Diagnostic 
biomarkers  











Elevated levels of ANXA2 in cases 
vs controls, higher levels associated 
with cancers at high-risk of 
recurrence   
Prognostic 
biomarker 












Proteomic analysis of culture media 
EVs. Validation of enrichment of 
LGALS3BP in high-risk EC 
patients, no association between 










Serum (dUC) Hsp20, Hsp22, 
alpha-B 
Crystallin  
Elevated levels of Hsp20, Hsp22 
and alpha-B Crystallin in EC. sHsp 









and 4003  
Culture 
media (dUC)  
miR-133a miRNA-133a was detected in EVs 








Serum (UC) miR-93, miR-
205 
 
Previously implicated oncogenes 
miR-93 and miR-205 were DE.  
miR-93 expression associated with 
EC overall survival  
Prognostic 
biomarker 






LGALS3BP Elevated levels of LGALS3BP 
protein in EC vs HC, and ECs with 
metastasis.  
LGALS3BP contributed to EC 















miRNAs miRNA seq found 49 DEGs 
Validated expression using ddPCR. 
miR-15a-5p had AUC= 0.813 for 
distinguishing stage I EC from HC, 
and was associated with muscular 






Fan et al. 
(2021) (103) 
EC n= 92 
HC n=102 
Serum (PEG) miRNAs: 143, 
195, 20b, 204, 
423, 484 
Expression between serum and EVs 




ddPCR – digital droplet polymerase chain reaction, DE – differentially expressed, DEGs – differentially expressed 
genes, dUC – differential ultracentrifugation, EC – endometrial cancer, EV – extracellular vesicle, HC – healthy 
controls, OC – ovarian cancer, PEG – polyethylene glycol-based precipitation, UC – ultracentrifugation 
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between EVs and cell-free plasma (104). Resultingly, EV, tissue and extracellular 
miRNA biomarkers can have differing performance and predictive ability (105), 
highlighting the novelty of EV biomarkers. Selective packaging suggests that enriched 
EV miRNAs are important in modifying cells more distant from the tumour (106). As 
such, comparisons between EV and tissue miRNA expression profiles may provide 
insight into where miRNA expression is most important, providing clues to their role in 
cancer progression. This also means miRNAs previously investigated in EC tissue or 
plasma require investigation within EVs and cannot be assumed to have the same 
expression profiles. miRNA studies can also identify genes and pathways involved in 
EC pathogenesis and the possible role of EVs within cancer progression. Recently, 
miR-15a was found to have both diagnostic and prognostic potential, with expression 
correlated with depth of invasion and aggressiveness of cancer (102). The usefulness of 
this study is two-fold, identifying miR-15a as a possible EC biomarker and as regulator 
of EC progression. Downstream gene target analysis could reveal underlying 
mechanisms involved in EC development.  
Our knowledge of EC EV miRNA biomarkers is thus far limited, with only a handful of 
studies investigating differential EV miRNA expression between EC cases and 
controls. The miRNAs that were differentially expressed in EVs in EC cases compared 
to healthy controls investigated in more than one study are presented in Table 4. Two 
studies have taken a non-biased approach to investigate a wide number of miRNAs, 
with Zhou et al. (102) identifying 49 differentially expressed genes (DEGs) using RNA 
sequencing and Roman-Canal et al. (98) identifying 114 DEGs using a 754 miRNA 
microarray. For eight miRNAs the expression pattern was the same in both studies, 
while four miRNAs had opposite expression patterns. The difference in biofluids and 
isolation methods used in these studies (serum and precipitation-based isolation (102), 
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and peritoneal lavage and differential UC (98)) may contribute to the limited number of 
overlapping DEGs. Of the DEGs present in both these studies, miR-21 and miR-200b 
had been previously investigated by Zavesky et al. (94) in urine EVs, finding no 
differential expression. Further contradictory results include Zheng et al. (91) finding 
miR-93 and miR-205 to be differentially expressed, which was not replicated by Zhou 
et al. or Roman-Canal et al.. Srivastava et al. (95) used a microarray to investigate 
miRNA expression, but the utility of this study is severely limited by the lack of 
statistical comparisons between expression in cases and controls. The absence of 
standardised methodologies for studying EVs is reflected by the wide range of EV 
isolation techniques used (see Table 3), contributing to the inconsistencies in 
expression patterns between studies and making comparisons difficult. Similarly, the 
use of various biofluids as EV sources further complicates the ability to draw 
comparisons between studies. These studies have provided a basis for future studies to 
begin further investigations from, highlighting miRNAs of interest to further investigate 
within EC EVs.  
Table 4: Expression patterns of miRNAs in EC compared to healthy controls 
investigated in more than one EV study 
Downregulated Mixed result 
miRNA Reference miRNA Reference 
miR-101 (98, 102) miR-20a  (94, 98) 
miR-130a (98, 102) (98, 102) miR-20b  (98, 103) 
miR-139  (98, 102) miR-21 (94, 98, 102) 
miR-219a  (98, 102) miR-29a  (94, 98) 
miR-222  (98, 102) miR-100  (94, 102) 
miR-885 (98, 102) miR-106b  (94, 102) 
  miR-126  (98, 102) 
  miR-143  (98, 102, 103) 
  miR-194 (98, 102) 
  miR-200b  (94, 98, 102) 
  miR-423  (98, 103) 
  miR-451a  (98, 102) 
  miR-1180  (98, 102) 
 
  16 
 
The lack of reproducibility has led to conflicting results between the limited number of 
EC EV studies, delaying preclinical progress and preventing clinical validation of 
candidate biomarkers. Technological progress and standardisation is required before 
EVs are likely to be used clinically in EC treatment and management. However, the 
unique role of miRNAs in cell communication provides insight into carcinogenic 
pathways, maintaining the value of pre-clinical studies while technological advances 
are in development. Ideally, many candidate EC biomarkers will be available for trials 
once EV isolation technology is optimised for clinical use.   
 
1.6 EVs and LNG-IUD treatment response 
Currently, there are no published studies investigating EVs in the context of LNG-IUD 
treatment response, highlighting an area requiring further research. As previously 
discussed, biomarker research into LNG-IUD treatment response has yielded some 
success but has not translated to clinically utilised biomarkers. EVs provide an exciting 
opportunity to advance this field and provide novel biomarkers that reduce the risk of 
opting for conservative early EC treatment. 
Evidence suggests that miRNAs can both regulate PR (107), and be regulated by 
progestins (108). Therefore, miRNAs may be critical in normal PR signalling 
pathways, and dysregulation of these miRNAs may be involved in the LNG resistance 
phenotype. With miRNAs being enriched within EVs, EVs are a promising avenue for 
identifying dysregulated miRNAs involved in LNG resistance. These molecules may 
then act as biomarkers of LNG treatment response, while also providing insight into the 
molecular mechanisms of resistance to progestin treatment.  
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Current clinical follow up for non-surgical treatment of endometrial cancer usually 
involves pipelle biopsies every three months. These biopsies are invasive and painful, 
and often need to be repeated due to poor tissue collection (109). With EVs abundant in 
bodily fluids, EV-based biomarkers could therefore facilitate the introduction of a 
liquid biopsy for more accessible LNG-IUD treatment monitoring.   
 
1.7 Relevance to Aotearoa 
EC is the most common gynaecological cancer in Aotearoa, with over 500 women 
diagnosed annually (110). Improving and expanding treatment options for EC is 
important for women in Aotearoa, as we have the fastest rising rates of EC in 
premenopausal women in the world (3). Māori and Pasifika women have higher rates of 
EC compared to non-Māori non-Pasifika women, with 17.7 and 32.4 per 100,000 
women respectively, vs 9.9 per 100,000 women (111). This increased risk is often 
attributed to the higher rates of obesity observed in these populations. However, once 
this is accounted for, estimates are that Pasifika women may still have double the risk 
of EC than European women (112). The higher rates of obesity mean these women may 
be less likely to be eligible for hysterectomy, the normal standard of care. 
Consequently, to ensure equitable health outcomes for all women living in Aotearoa we 
need a range of safe and accessible EC treatments.  
Current EC treatment may not be acceptable as hysterectomy is culturally inappropriate 
for some women. For example, the female reproductive tract and whare tangata (uterus) 
is tapu and of deep spiritual importance to Māori (113). This may make hysterectomy 
undesirable in te ao Māori (the Māori worldview). Therefore, safe and culturally 
accessible alternatives to hysterectomy are very relevant in the Aotearoa context. 
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LNG-IUD treatment allows women to retain their uterus which is appealing for many 
women, not just younger women who wish to retain their fertility. However, the regular 
pipelle biopsies required post LNG-IUD treatment is burdensome and can be a barrier 
to access. EV-based LNG-IUD predictive biomarkers may allow for a liquid biopsy to 
replace pipelle biopsies, providing an exciting opportunity to widen access to this 
treatment by providing a more acceptable monitoring process for women living in 
Aotearoa. This may particularly benefit women who live rurally or a long distance from 
a specialist centre, and women for which the health care system is currently 
inaccessible. Therefore, this research project is highly relevant to women in Aotearoa, 
and the translatability of this study aims to have both biomedical and social benefits.  
 
1.8 Aims of research  
This aim of this study was to identify miRNA biomarkers present in EVs which may be 
used to predict response to LNG-IUD treatment in early EC using an in vitro model.  
This project builds on previous research conducted in our lab, using the same cell lines 
which have previously been used to explore cell behaviour and DEGs of LNG-IUD 
treatment resistance. The current study takes a new approach by investigating miRNA 
biomarkers in EVs. This research is novel, being the first study to investigate EVs as 
biomarkers of LNG response.  
We hypothesised that EVs isolated from resistant and sensitive cell lines would contain 
different levels of miRNAs which may act as biomarkers of LNG response. We also 
hypothesised that these miRNAs would also be detectable in EVs from patient plasma.  
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Objectives: 
1. Isolate EVs from cell culture media of LNG resistant and sensitive commercial 
cell lines, and characterise the size, distribution and concentration of the EVs 
2. Investigate the expression levels of candidate miRNA biomarkers in EVs using 
RT-qPCR and perform pathway enrichment analysis 
3. Validate expression of candidate miRNAs in EVs isolated from EC patient 
plasma 
 
1.9 Study design 
The workflow of scientific experiments conducted is presented in Figure 3. Firstly, 
ongoing resistance to LNG treatment in the resistant cell lines was demonstrated 
through a proliferation assay. EVs were then isolated from the culture media of 
resistant and sensitive cell lines. The presence of EVs was demonstrated and the size, 
concentration and morphology characterised through Western blots, tunable resistive 
pulse sensing (TRPS) and transmission electron microscopy (TEM). RNA was 
extracted from EVs, and the expression of candidate miRNAs selected from the 
literature investigated using RT-qPCR. Pathway enrichment analysis of the downstream 
gene targets of the miRNAs most differentially expressed was performed. Finally, 
candidate miRNA expression was validated in EVs from plasma of EC patients.  
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Figure 3: Flow chart of study design. Numbers correspond to relevant methods 
sections. EVs – extracellular vesicles, RT-qPCR – quantitative reverse transcription 
polymerase chain reaction, TEM – transmission electron microscopy, TPRS – tunable 
resistive pulse sensing. 
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 Methods 
2.1 Ethical approval  
This study received ethical approval from the University of Otago Human Ethics 
Committee (Health) for the investigation of molecular biomarkers in gynaecological 
cancer (H20/002). This included ethical approval for the use of patient samples 
collected prior for biobanking purposes (HDEC 15/CEN/143). This study was approved 
by Ngāi Tahu Research Consultation Committee at the University of Otago and 
Research Advisory Group - Māori (RAG-M) for tissue collection at Capital and Coast 
District Health Board (CCDHB).   
 
2.2 Cell culture  
 MFE296 and MFE319 cell lines 
Immortalised endometrial cancer cell lines MFE296 and MFE319 were gifted from the 
Gynaecological Cancer Research Group UNSW Sydney, Australia. LNG treatment 
resistant clones (from now on named MFE296R and MFE319R) were previously 
developed in our lab through continuous long-term exposure to LNG at an IC30 
concentration (114). Control cell lines sensitive to LNG treatment (MFE296S and 
MFE319S) were passaged alongside the resistant lines and treated with dimethyl 
sulfoxide (DMSO) (Sigma-Aldrich, #D5879) as a control.   
MFE296 and MFE319 cell lines were grown according to suppliers’ instructions. 
Media for both cell lines was supplemented with EV-depleted foetal bovine serum 
(FBS) (Moregate Biotech, #FBSF). FBS was diluted 1:4 in culture media and 
centrifuged at 100,000 x g for 16 hours at 4°C, to remove contaminating EVs. 
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Additional media was then added to reach the desired FBS concentration to make 
complete media. Complete media was then filtered with a 0.22uM filter (Corning, 
#COR431097).  
MFE296 cell lines were grown in minimum essential media (MEM) (Thermo Fisher 
Scientific, #11095080), supplemented with 10% EV-depleted FBS. MFE296R media 
contained 450µM of LNG (Sapphire Bioscience, #S1727) dissolved in DMSO, and 
MFE296S media contained 0.5% DMSO. MFE319 cell lines were grown in 40% 
MEM, 40% Roswell Park Memorial Institute (RPMI) media (Thermo Fisher Scientific, 
#11875093), with 20% EV-depleted FBS. MFE319R media contained 350µM of LNG 
and MFE319S media contained 0.4% DMSO. The concentration of LNG used for each 
cell line was determined previously in our laboratory using the IC30 method to create 
resistant cell lines. Media for both cell lines contained 1% penicillin-streptomycin. 
Cells were kept at 37°C in 5% CO2. Cells were passaged routinely at 80% confluency. 
Media was changed every 2-3 days. Cells were confirmed to be free of mycoplasma 
using the MycoProbe Mycoplasma Detection Kit (R&D Systems, #CUL002B), with 
testing conducted every three months.  
 Proliferation assay 
Cells from each cell line were seeded at a 2 x 105 density in triplicate on a 96-well 
plate. Media only wells were included for each cell line. After 24 hours, media was 
refreshed and 10µL of CCK8 (Dojindo Molecular Technologies, #CK04) was added to 
each well. Absorbance at 450nm was then measured three hours after the addition of 
CCK8 using the Multiskan GO Microplate Spectrophotometer (Thermo Scientific, 
#N10588). Following this, treated media containing either LNG or DMSO was added 
to the appropriate wells for each cell line. The process was repeated 24, 48 and 72 
hours after the first CCK8 addition. The first absorbance reading provided the cell 
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density at the 0-hour time point, which was used as the baseline measure to which 
subsequent absorbance values were normalised to. The experiment was carried out in 
biological duplicate for each cell line.  
 
2.3 EV isolation using size exclusion chromatography 
 Cell culture media sample collection 
Cell culture media was collected during media replacement (every 2-3 days) and 
centrifuged at 2,000 x g for 10 minutes. The resulting supernatant was collected and 
slowly frozen in isopropanol and stored at -80°C.  
 EV isolation from cell culture media 
EVs were isolated from the culture media through size exclusion chromatography 
(SEC) using an automated fraction collector (Izon Science) with qEV10/70nm columns 
(Izon Science, #SP4). The column contains porous resin particles, with large particles 
unable to enter the pores leading them to move quickly through the column and elute 
first. Smaller particles enter the pores, slowing their movement and causing them to 
elute later.  
Samples were rapidly thawed at 37°C and centrifuged at 2,000 x g for 10 minutes to 
remove any remaining debris prior to EV isolations. The column was flushed with 
120mL of phosphate-buffered saline (PBS) (Gibco, #18912014) before the addition of 
10mL of sample. Four 5mL EV rich fractions (fractions 5-8) were collected and pooled. 
These fractions were collected based on manufacturer recommendations to maximise 
EVs and minimise protein contamination. 4mL of the fractions were concentrated to 
170µL using an Amicon Ultra-4 10 kDa Centrifugal Filter Unit (Merck Millipore, 
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#UFC8010) by centrifuging at 4,000 x g for 14 minutes. Concentrated EVs were then 
stored at -80°C for TRPS analysis. The remaining 16mL of pooled fractions were 
concentrated through ultracentrifugation at 100,000 x g at 4°C for 16 hours and 
resuspended in Exosome Resuspension Buffer, from the Total Exosome RNA & 
Protein Isolation Kit (Invitrogen, #4478545).  
For Western blotting, EV pellets were resuspended in a total of 70µL of Exosome 
resuspension buffer and stored at -80°C. For RNA extraction, EV pellets were 
resuspended in 200µL of Exosome Resuspension Buffer used immediately for RNA 
extraction.  
 
2.4 Characterisation of EVs from cell culture media  
Following isolation from cell culture media, EV preparations were characterised to 
assess their size distribution, concentration, morphology and purity.  
 Tunable resistance pulse sensing analysis 
The qNano Gold (Izon Science) was used to perform TRPS measurements to assess the 
size and concentration of the EVs. The instrument was set up and calibrated according 
to the manufacturer’s instructions. A Nanopore 200 (Izon Science, #NP200) that 
captures particles sized between 85-500nM was utilised. Calibration particles with a 
diameter of 200nm (Izon Science, #CPC200) were diluted 1:200 and used to calibrate 
samples. The stretch applied ranged from 46.84 to 48.11mm and the voltage used 
ranged from 0.28 to 0.44V. EV samples were rapidly thawed at 37°C and then 
centrifuged for five minutes at 2,000 x g prior to running. During calibration and 
sample measurement, a minimum particle count of 500 was reached with the particle 
rate and current kept as constant as possible (Figure 4). Analysis of resulting data was 
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performed using the Izon Control Suite (version 3.3) to determine the concentration and 
the size distributions of the particles in the sample. Biological triplicates for each cell 
line were measured, with EVs isolated from media collected from three different 
passages for each cell line.  
  
Figure 4: Representative images of TRPS analysis of EVs isolated from cell culture 
media. A) Signal trace graph measuring current (nA) against time (s) during sample 
measurement. Resistive pulses seen as spikes in the current trace correspond to EV 
volume, caused by EVs passing through the nanopore. B) Particle count against time (s) 
 
 Negative stain transmission electron microscopy  
Cell culture media was harvested and centrifuged for 10 minutes at 2,000 x g. EVs were 
isolated from 10mLs of the resulting supernatant using qEV10/70nm columns as 
previously described. All four 5mL fractions were pooled and concentrated using 
Amicon Ultra-15 10 kDa Centrifugal Filter Unit (Merck Millipore, #UFC9010) by 
centrifuging at 4,000 x g for 40 minutes. The concentrated EVs were stored at 4°C.  
Negative staining was carried out by Richard Easingwood at OMNI Electron 
Microscopy, University of Otago Dunedin. 10µL of sample was placed onto a carbon 
coated 300 mesh copper grid. After 60 seconds the excess sample was removed by 
blotting and 10µL of 1% phosphotungstic acid (PTA) in water was applied to the grid 
to contrast the sample. The PTA was blotted off immediately. The grids were then 
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viewed in a Philips CM100 BioTWIN transmission electron microscope (Philips/FEI 
Corporation), and images captured using a MegaView lll digital camera (Soft Imaging 
System GmbH). 
 Western blot  
EV lysate was prepared by dissolving the EV pellet following ultracentrifugation in 
Exosome Resuspension Buffer as previously described in Methods 2.3.2. A BCA 
Protein Assay (Thermo Scientific, #23225) was first performed to confirm protein 
content from EVs. In brief, 10uL of sample or albumin standards was added to a 96-
well plate. Albumin standards were plated in triplicate, while EV lysate was plated in 
duplicate due to the limited sample available. To each well, 80uL of BCA working 
reagent was added before incubating the plate for 30 minutes at 37°C. Absorbance was 
measured using the Multiskan GO at 562nm. The absorbance of albumin standards was 
used to generate a standard curve which was then used to determine protein 
concentration of each sample.  
EV lysate and plasma were added to LDS Sample Buffer (4x) (Invitrogen, #NP0007) to 
make a 1x dilution prior to heating to 75°C for five minutes. A plasma sample with 
high lipid content was used as a positive control for ApoB blots. Samples were then 
loaded on a 4-20% Tris-Glycine gel (Invitrogen, #XP04200BOX), with 30µL loaded 
for EV samples and 5µL for plasma controls. The amount of protein loaded ranged 
from 0.414µg to 6.32µg per well. Due to low protein levels in EV lysate and blotting 
not being quantitative, the amount of protein loaded was not standardised. Instead, the 
maximum possible amount was used to maximise the ability to detect protein presence. 
To assess protein size, 10µL of Spectra Multicolour Broad Range Protein Ladder 
(Thermo Scientific, #26634) was loaded. Gels were run in Tris Glycine SDS Running 
Buffer (Invitrogen, #LC2675) at 120V for 90 minutes.  
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Samples were transferred onto a 0.45μm nitrocellulose membrane (Thermo Scientific, 
#88018) using the Power Blotter Station (Invitrogen, #PB0010) at 1.3A and 25V for 7 
minutes. Membranes were blocked for one hour at room temperature with 3% BSA (pH 
Scientific, #PH100) in 0.1% Tris-buffered saline/Tween (TBST). Membranes were then 
incubated with the desired primary antibody (Table 5) diluted in blocking solution 
(1:200 dilution) overnight at 4˚C. Membranes were washed three times with TBST for 
five minutes, then were incubated with the appropriate secondary antibody (Table 6) 
diluted in blocking solution (1:1000 dilution) for one hour at room temperature. Three 
5-minute TBST washes were performed, then membranes were developed with the 
SuperSignal West Pico chemiluminescent substrate (Thermo Scientific, #34577) in the 
dark for five minutes. Membranes were imaged using the iBright CL100 (Invitrogen). 
Band size was estimated visually using the protein ladder.  
Blots were carried out in biological triplicate for each protein of interest by isolating 
EVs from three media samples collected from different passages for each cell line.  
Table 5: Primary antibodies used for Western Blotting 
Target Company Catalogue number Host/Isotype Dilution 
ApoB Thermo Fisher Scientific PA5-86101 Rabbit/IgG 1:200 
CD9 Santa Cruz Biotechnology sc-13118 Mouse/IgG1 1:200 
TSG101 Thermo Fisher Scientific PA5-81094 Rabbit/IgG 1:200 
 
Table 6: Secondary antibodies used for Western blotting 
Target Company Catalogue number Host Dilution 
Mouse IgG Santa Cruz Biotechnology sc-525409 Recombinant 1:1000 
Rabbit IgG Abcam ab205718 Goat 1:1000 
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2.5 Gene expression analysis 
 RNA extraction from cell culture media EVs 
Total RNA was isolated and purified from concentrated EVs using the Total Exosome 
RNA & Protein Isolation Kit (Invitrogen, #4478545) and RNA Clean & Concentrator-5 
(Zymo Research, #R1013). These two kits were combined so RNA could be eluted in a 
smaller volume, due to the low RNA yield from culture media EVs.  
Using the Total Exosome RNA & Protein Isolation Kit, one volume of denaturing 
solution was added to the resuspended EVs and incubated on ice for five minutes. 
Following this, one volume of acid-phenol:chloroform was added and centrifuged 
13,000 x g for 30 seconds. The aqueous phase was transferred to a new tube and 1.25 
volumes of 100% ethanol was added.  
To carry out RNA purification, the sample was then transferred to the Zymo-Spin IC 
Column from the RNA Clean & Concentrator-5 kit and centrifuged at 10,000 x g for 30 
seconds. To the column, 400µL of RNA prep buffer was added followed by 
centrifugation at 10,000 x g for 30 seconds. The sample was washed with 700µL of 
RNA Wash Buffer then centrifuged at 10,000 x g for 30 seconds. A second wash with 
400µL of Wash Buffer with a one-minute centrifuge at 10,000 x g was carried out. The 
RNA was then eluted from the column using 15µL of nuclease free water, centrifuging 
first at 800 x g for one minute, then at 12,000 x g for 30 seconds. Eluted RNA was 
stored at -80°C.  
 cDNA synthesis 
RNA extracted from EVs was converted to cDNA using the TaqMan™ Advanced 
miRNA cDNA Synthesis Kit (Applied Biosystems, #A28007) according to the 
manufacturer’s instructions. A no reverse transcriptase (no-RT) control was included to 
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identify possible DNA contamination. Following the adaptor ligation reaction, the 
product was split into two. One sample received the Reverse Transcription Mastermix 
according the manufacturer’s instructions, while the other sample received a no-RT 
Mastermix. The no-RT mastermix contained nuclease free H2O in place of 10x RT 
enzyme mix. The sample receiving the no-RT mastermix became the no-RT cDNA. 
cDNA was stored at -20°C.  
The miR-Amp reaction was then carried out according to manufacturer’s instructions in 
both the RT and no-RT cDNA samples, to increase the concentration of miRNAs in the 
sample. The miR-Amp cDNA product was stored at -20°C until use in RT-qPCR.  
 RT-qPCR 
To investigate miRNA candidate gene expression in cell culture EVs, RT-qPCR was 
carried out. miRNAs were selected from the literature based on previous evidence of 
involvement in EC, and three miRNAs were selected from RNA sequencing data 
previously carried out on the cell lines.  
RT-qPCR was carried out according to the TaqMan® Advanced miRNA Assays 
(Applied Biosystems, #A25576) protocol. Each well contained 5µL of TaqMan® Fast 
Advanced Master Mix (2x), 0.5µL of TaqMan® Advanced miRNA Assay (20X) 
primers and 2µL of nuclease free water. Specific primers used are listed in Table 7. The 
miR-Amp cDNA was diluted 1:4 in nuclease free water, and 2.5µL added to each well.  
PCR thermal cycling conditions were as follows: 95°C for 20 seconds, followed by 40 
cycles of 95°C for 3 seconds and 60°C for 30 seconds. No-RT cDNA and water 
controls were included to identify possible contamination. miRNA expression levels 
were measured using threshold cycle values (Ct), with an automatically determined 
threshold (Figure 5). Experiments were run in triplicate, with technical triplicate Ct 
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values averaged. The Ct cut off value was 40. When miRNA levels were too low to be 
detected, a Ct value of 40 was assigned. Biological triplicates of RT-qPCR were 
completed.  
Table 7: TaqMan Advanced miRNA Assays used in RT-qPCR 
Assay name  Assay ID Reason chosen 
hsa-miR-16-5p 477860_mir Endogenous reference gene 
hsa-miR-25-5p 478786_mir RNA sequencing data from cell lines 
hsa-miR-31-5p 478015_mir EV EC biomarker literature (98) 
hsa-miR-93-3p 478209_mir EV EC biomarker literature (91) 
hsa-miR-133a-3p 478511_mir EC biomarker literature (101) 
hsa-miR-146b-3p 483103_mir EC biomarker literature (115) 
hsa-miR-182-5p 477935_mir EV EC biomarker literature (98) 
hsa-miR-183-5p 477937_mir EC biomarker literature (116) 
hsa-miR-186-5p 477940_mir Endogenous reference gene 
hsa-miR-200b-3p 477963_mir EV EC biomarker literature (98) 
hsa-miR-200c-3p 478351_mir EV EC biomarker literature (98) 
hsa-miR-205-5p 477967_mir EV EC biomarker literature (91) 
hsa-miR-423-5p 478090_mir Endogenous reference gene 
hsa-miR-520d-5p 478616_mir Endogenous reference gene 
hsa-miR-1244 478651_mir RNA sequencing data from cell lines 
hsa-let-7b-5p 478576_mir RNA sequencing data from cell lines 
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Figure 5: Representative image of RT-qPCR amplification curve (miR-16, cell culture 
EVs) 
 
A visual summary of the workflow of isolation and downstream applications of cell 
culture EVs is demonstrated in Figure 6.  
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Figure 6: Workflow of isolation and downstream analysis of cell culture media EVs. 
Made using BioRender.  
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2.6 Enriched pathway analysis of miRNA targets 
miRTarBase (release 8.0) (117) was used to generate a list of validated gene targets of 
miR-133a-3p, miR-93-3p and miR-205-5p. Pathway analyses were conducted using 
Database for Annotation, Visualisation and Integrated Discovery (DAVID) (118). 
Kyoto Encyclopedia of Gene and Genomes (KEGG) pathway analyses of miRNA 
targets were applied to identify pathways that were overrepresented in the genes 
targeted by each miRNA. Significance for enriched pathways was set at p<0.05.  
 
2.7 Validation of miRNA expression in patient plasma EVs 
 Patient samples 
Patients undergoing treatment for EC at Wellington Regional Hospital were invited to 
donate their tissue to the gynaecological cancer biobank managed by our laboratory. All 
patients provided informed consent to the donation of their tissue and were free to 
withdraw at any time. Patient information was stored securely in the REDCap database 
and provided to the researcher by the research assistant without any identifying 
information to ensure the maintenance of confidentiality. The information provided to 
the researcher included the patient’s age and BMI, the stage, grade and morphology of 
their cancer, and the treatment they received.  
Patient plasma samples were collected from the biobank; samples from women who 
had treatment with the LNG-IUD prior to hysterectomy were identified (n=2). Two 
samples from women diagnosed with early stage low grade (FIGO IA Grade I 
endometrioid) tumours who were not treated with the Mirena were collected for 
comparison. These groups were chosen as the closest representation of the resistant and 
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sensitive cells. The no response group were resistant to LNG treatment, and the no 
treatment group are similar the sensitive cells as they were not exposed to LNG.  
 EV isolation from plasma  
EVs were isolated from patient plasma media using an automated fraction collector 
with qEVoriginal/70nm columns (Izon Science, #SP1). Plasma was rapidly thawed at 
37°C and centrifuged for 2,000 x g for 5 minutes prior to EV isolations. The column 
was flushed with 15mL of PBS before the addition of 500µL of sample. Three 1.5mL 
fractions were collected and pooled. The pooled fractions were concentrated through 
ultracentrifugation at 100,000 x g at 4°C for 2 hours and resuspended in 200µL 
Exosome Resuspension Buffer for RNA extraction.  
 RNA extraction from plasma EVs 
Total RNA was isolated and purified from concentrated EVs using the Total Exosome 
RNA & Protein Isolation Kit according to the manufacturer’s instructions. One volume 
of denaturing solution was added to the resuspended EVs and incubated on ice for five 
minutes. Following this, one volume of acid-phenol:chloroform was added and 
centrifuged 13,000 x g for 30 seconds. The aqueous phase was transferred to a new tube 
and 1.25 volumes of 100% ethanol was added. The sample was then added to the filter 
cartridge and centrifuged. Three RNA washes were carried out, centrifuging for 15 
seconds at 10,000 x g after the addition of each wash solution. To elute the RNA, 50µL 
of elution solution preheated to 95°C was added to the filter cartridge and centrifuged 
first at 200 x g for one minute, then at 10,000 x g for 30 seconds. Eluted RNA was then 
stored at -80°C.  
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 RT-qPCR 
RNA was converted to cDNA as outlined in 2.5.2. RT-qPCR was then performed as 
described in 2.5.3 to validate the expression of the candidate miRNAs in patient plasma 
EVs.  
 
2.8 Statistical Analysis 
Prism v9.2.0 (GraphPad) was used to perform all statistical analyses. All data is 
presented as the mean ± SD unless otherwise stated. Technical and biological triplicates 
were carried out for each experiment, except for the proliferation assay which was 
carried out in biological duplicate. An F-test was conducted to test for differences in 
variance prior to t-test analysis. Significance was set at p<0.05 for each statistical 
analysis.  
 Assessing difference in proliferation  
The mean absorbance at each time point was normalised to the 0-hour time point. An 
unpaired student’s t-test was carried out to assess differences in proliferation at 24, 48 
and 72 hours between sensitive and resistant cell lines.  
 Evaluating endogenous reference gene expression 
miR-16 and miR-423 were assessed for their suitability as reference genes, as 
expression of endogenous controls should not significantly differ between groups. An 
unpaired t-test was carried out on mean Ct values of miR-16 and miR-423 in sensitive 
and resistant cells, for both cell lines. The geometric mean of both reference genes was 
also assessed using an unpaired t-test.  
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 qPCR data analysis 
The geometric mean of reference genes miR-16 and miR-423 were used to normalise 
the Ct values of the genes of interest using the ΔCt method (119). Results are presented 
as ΔCt±SD with individual values plotted. An unpaired t-test was performed to 
determine differences in ΔCt values between resistant and sensitive cell lines, and 
between no treatment and no response groups.  
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 Results 
3.1 Cell proliferation in resistant cells is unaffected by 
LNG treatment 
Proliferation rate was determined by changes in cell density, measured by CCK8 
absorbance. Normalised absorbance levels did not significantly differ between sensitive 
and resistant MFE296 or MFE319 cell lines at any time point measured (Figure 7A-B), 
as assessed by unpaired t-test. As cell density was increasing at a similar rate, the 
cellular proliferation of resistant cells while cultured in LNG was similar to that of the 
corresponding sensitive cells in both cell lines.  










































Figure 7: Cellular proliferation of sensitive and resistant cell lines. Resistant cells were 
cultured in LNG treated media (MFE296: 450μM, MFE319: 350μM) while sensitive 
cells were cultured in control media (MFE296: 0.5% DMSO, MFE319: 0.4% DMSO). 
Proliferation rate is measured by CCK8 absorbance levels normalised to the 0 hour time 
point. A) MFE296 cell line. B) MFE319 cell line. Results are presented as mean ± SD 
(n=2). Difference in absorbance at each time point for each cell line was tested using an 
unpaired t-test, with significance set at p<0.05. No significant difference in cell density 
was observed at any time points measured.  
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3.2 EV Characterisation 
 EV Size and Concentration by TRPS analysis 
 Size distribution of EVs 
The particle size distribution was approximately normally distributed for all cell lines 
(n=3). Representative size distribution graphs from each cell line are presented in 
Figure 8, and images for all samples can be found in the Appendix 1 (Figure S1). The 
mean size of EVs was consistent across the cell lines, with a mean particle size of 
247±11.59nm for the MFE296R cells compared to 248±17.93nm for the MFE296S 
cells, and 257±12.86 and 260±12.42nm for the MFE319 resistant and sensitive cells, 
respectively. The minimum particle size was similar between cell lines, with the 
smallest particle measured ranging from 133±39.32nm to 153±9.51nm in the 
MFE296R and MFE319R lines, respectively. The maximum particle size measured 
showed more variation across cell lines, with the largest particle measured being 
713±227.58nm in the MFE296R line and 1072±130.77nm in MFE319R cell line. 
Particle size distribution data is summarised in Table 8.  
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Figure 8: Representative size distribution histogram of EVs as measured by TRPS. 
Concentration of EVs (particles/mL) is plotted against particle diameter (nm). A) 
MFE296S. B) MFE296R. C) MFE319S. D) MFE319R.  
 
Table 8: Size range of EVs measured by TRPS 
Cell line  Minimum (nm) Maximum (nm) Mean (nm) 
MFE296S 153±9.51 942±154.50 248±17.93 
MFE296R 133±39.32 713±227.58 247±11.59 
MFE319S 141±14.15 967±95.10 258±12.86 
MFE319R 153±2.89 1072±130.77 260±12.42 
Values are presented as the mean ± SD (n=3) 
 
 Concentration of EV preparations 
EV concentrations were similar between the resistant cells for both MFE296 and 
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cell line with a mean concentration of 7.08x108±2.93x108 particles/mL, followed by the 
MFE319R cells which had a concentration of 1.55x109±1.07x109 particles/mL. In the 
MFE296 cell line, there was 5.42x109±1.96x109 particles/mL in the resistant line, and 











































Figure 9: Concentration of EVs from cell culture media as measured by TRPS. Data is 
presented as the mean ± SD (n=3) with individual values plotted.  
 
 Visualisation of EV morphology by negative stain TEM 
Negative stain TEM allowed for the visualisation of individual EVs from a pooled 
sample of isolated EVs from each cell line (Figure 10). In all cell lines most EVs had a 
round morphology. The presence of an intact double membrane can be observed, 
demonstrating the particles isolated were intact vesicular structures. Visually, there was 
a range of differently sized particles, and all cell lines had high levels of small EVs 
around 30nm. There was some debris visible in the EV preparations. Subsequent 
protein analysis (described in 3.2.3) of EV preparations demonstrated that these were 
not lipoproteins, which commonly contaminate EV samples.  






Figure 10: Negative stain electron microscopy images of EVs isolated from cell culture 
media. EVs were isolated from fresh cell culture media and all fractions pooled and 
concentrated for imaging. Arrows indicate example intact vesicles. A) MFE296R. B) 
MFE296S. C) MFE319R. D) MFE319S.  
 
 Protein analysis through Western blotting 
Western blots confirmed the presence of EV specific proteins, and the absence of 
proteins that indicate the presence of co-isolated contaminants. Representative images 
for each protein investigated are presented in Figure 11, and the full blot image for each 
biological replicate can be found in Appendix 2 (Figures S2-4).  
CD9, a transmembrane protein, was detected in all four cell lines with a band at 27kDa, 
similar to the predicted band size based on the molecular weight of 24kDa (Figure 11). 
TSG101, a cytosolic protein, was also present in all cell lines with an observed band 
size of 50kDa estimated from the protein ladder, slightly higher than the predicted band 
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Apolipoprotein B was not detected in the EV samples of any cell lines, while it was 
detected in the plasma controls (Figure 11). Bands were present in the plasma controls 
at the expected size. ApoB has a molecular weight of 210kDa, and bands were 
observed around 240kDa. In some of the plasma controls there were additional bands 
present, with significant noise between 100kDa to 260kDa. There was non-specific 
binding in some of the EV lysates with a small band present at around 14kDa 
(Appendix 2, Figure S4). 
 
Figure 11:  Detection of EV specific protein markers TSG101 and CD9, and 
contaminant marker ApoB in EV lysates from cell culture media. Plasma was included 
as a positive control for ApoB.  
 
3.3 Gene expression analysis of culture media EVs 
through RT-qPCR 
 Endogenous reference gene evaluation  
To assess the expression of candidate reference genes selected from the literature, miR-
16 and miR-423, unpaired t-tests were performed on the Ct values of the sensitive and 
resistant cells lines. There was no difference in EV miR-16 expression in the MFE296 
cell lines (p=0.472) or in the MFE319 cell lines (p=0.851). Similarly, no difference in 
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EV miR-423 expression was observed in MFE296 (p=0.878) or MFE319 (p=0.703) cell 
lines. Mean Ct values are displayed in Table 9, and Ct values for each biological 
replicate can be found in Appendix 3 (Table S1-S2).  
miR-520d and miR-186 were also tested for reference gene suitability. Expression of 
miR-520d was too low to be detected with the sensitivity of the assay, with an average 
Ct value of above 35 in EVs from all cell lines (Appendix 3, Table S3). miR-186 was 
only moderately expressed and showed highly varied expression, so therefore 
unsuitable for use as an endogenous control (Table S3).  
The geomeans of miR-16 and miR-423 in the resistant and sensitive cell lines were also 
analysed using an unpaired t-test. The geomean of the reference genes did not differ 
between sensitive and resistant cells in the MFE296 (p=0.650) or the MFE319 cell lines 
(p=0.934) (Table 9).  
Based on these results, miR-16 and miR-423 were used as endogenous controls for 
normalisation of Ct values in RT-qPCR data analysis.  
Table 9: Ct values of candidate endogenous reference genes 
 MFE296R MFE296S MFE319R MFE319S 
miR-16-5p 28.45±1.30 26.33±3.36 27.11±2.42 27.59±1.14 
miR-423 25.27±2.97 24.86±1.95 25.81±1.61 25.19±1.41 
Geomean 26.75±2.11 25.58±2.63 26.50±2.00 26.36±1.14 
Values are presented as mean ± SD (n=3) 
 
 Expression of candidate miRNAs in cell culture media EVs 
RT-qPCR was conducted to measure the levels of candidate miRNA biomarkers 
present in EVs in LNG resistant and sensitive MFE296 and MFE319 cell lines.  
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miRNAs that had average Ct values over 35 had expression too low to be detected with 
the sensitivity of the assay, and so were not included in further analysis. This included 
miR-31, miR-146b and miR-183 which could not be detected any of the four cell lines. 
In the MFE296 cell line this also included miR-133a, miR-200b and miR-205. In the 
MFE319 cell lines, miR-93 and miR-200b also had undetectable expression. The Ct 
values for all miRNAs are presented in Table 10. 
Table 10: Ct values from RT-qPCR of target miRNAs in EVs from cell culture media 
Gene MFE296R MFE296S MFE319R MFE319S 
miR-25-5p 27.27±0.81 27.53±2.01 27.56±2.00 28.07±1.14 
miR-31-5p 40.00±0.00 39.82±0.26 40.00±0.00 38.12±2.57 
miR-93-5p 38.93±1.15 32.62±3.03 35.65±2.24 38.85±0.64 
miR-133a-3p 38.81±1.68 38.01±1.12 36.92±2.42 30.01±4.09 
miR-146b-3p 38.70±1.84 40.00±0.00 38.78±1.73 35.95±3.51 
miR-182-5p 35.19±3.04 29.87±3.63 33.19±4.83 31.64±3.69 
miR-183-5p 38.93±1.51 35.86±3.36 38.30±2.40 36.76±2.46 
miR-200b-3p 38.92±1.52 37.42±3.24 38.27±2.45 32.56±1.66 
miR-200c-3p 34.83±2.77 36.70±1.44 34.00±4.45 30.13±1.68 
miR-205-5p 38.76±1.75 40.00±0.00 36.70±4.66 27.77±1.71 
miR-1244 25.93±3.15 23.76±2.05 25.07±1.76 24.41±1.64 
let-7b-5p 28.31±3.35 24.22±2.17 27.68±0.86 28.81±1.13 
Values are presented as mean ± SD (n=3) 
 
 MFE296 EV miRNA expression 
miR-93 and miR-182 expression was only detected in EVs derived from the sensitive 
cell line. miR-200c had weak expression in the MFE296R EVs and no expression was 
detected in the sensitive cell EVs. miR-1244, miR-25 and let-7b were strongly 
expressed in EVs from both cell lines. Gene expression was normalised to reference 
gene geomean of each biological replicate. The expression of these genes was found to 
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not be significantly different between EVs from sensitive and resistant cells, as assessed 
by an unpaired t-test (p>0.05) (Figure 12A).  
 MFE319 EV miRNA expression 
There was moderate expression of miR-182 and miR-200c detected in EVs from both 
sensitive and resistant cell lines, with average Ct values of above 30. miR-25, miR-1244 
and let-7b had strong expression in both cell lines. miR-205, miR-200b and miR-133a 
were found to only be expressed in EVs from the sensitive cell line. Gene expression 
data was normalised to the reference gene geomean of each biological replicate. There 
was no difference in normalised expression in EVs between the sensitive and resistant 
cells lines for any of the miRNAs investigated, as assessed by unpaired t-tests (p>0.05) 
(Figure 12B).  
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Figure 12: Expression of candidate miRNAs in EVs from MFE296 and MFE319 cell 
lines. RT-qPCR was performed, and Ct values normalised to the geomean of reference 
genes miR-16 and miR-423 (ΔCt). A) ΔCt values of candidate miRNAs expressed in 
MFE296S and MFE296R cell lines. No expression of miR-93 in MFE296R cells or 
miR-200c in MFE296S cells was detected. B) ΔCt values of candidate miRNAs 
expressed in MFE319S and MFE319R cell lines. No expression of miR-205, miR-133a 
or miR200b was detected in the MFE319R cell line. Results presented as the mean ± 
SD (n=3) with individual values plotted. Unpaired t-tests were performed to assess 
difference in normalised gene expression levels, with significance set at p<0.05. No 
statistically significant differences in expression were found. 
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3.4 Pathway enrichment analysis of miRNA targets 
miR-133a, miR-93 and miR-205 were selected for downstream target gene analysis as 
the p-value for these genes was close to significance (MFE319: miR-133a p=0.088 and 
miR-205 p=0.070, MFE296: miR-93 p=0.071). With a larger sample size giving 
increased statistical power, there may be a difference in expression of these genes. 
Therefore, these miRNAs warranted further investigation.  
Using the miRTarBase database, lists of verified gene targets of each miRNA were 
collated. For miR-133a-3p there were 131 target genes, 269 for miR-93-3p and 182 for 
miR-205-5p. A full list of the target genes for each miRNA can be found in Appendix 4 
(Tables S5-7).  
 Enriched pathways of miR-133a target genes  
KEGG Pathway analysis using functional annotation in the DAVID database identified 
29 enriched pathways. The top 10 most enriched pathways are displayed in Figure 13A. 
The pathways were all cancer related, with three of the enriched pathways being 
specific cancers; prostate, pancreatic and glioma. Notably, the enriched pathways HIF-
1, PI3K-Akt, Ras, Rap1 and focal adhesions are associated with cancer progression, 
having roles in angiogenesis, cell survival and proliferation, and metastasis.  
 Enriched pathways of miR-93 target genes  
KEGG Pathway analysis using functional annotation in the DAVID database identified 
eight enriched pathways. The five pathways that had statistically significant enrichment 
(p<0.05) are displayed in Figure 13B. The target genes were involved in cell adhesion, 
with tight and adherens junctions as enriched pathways.  
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 Enriched pathways of miR-205 target genes  
KEGG Pathway analysis using functional annotation in the DAVID database identified 
17 enriched pathways, with the top ten most enriched pathways displayed in Figure 
13C. Most enriched pathways were cancer related. Of interest, the Hippo signalling 
pathway was enriched, which regulates cell proliferation and apoptosis.  
 





Figure 13: KEGG pathway enrichment analysis of downstream targets of miR-133a-3p 
miR-93-3p and miR-205-5p. Validated targets of each miRNA from miRTarBase were 
analysed using DAVID to identify significantly enriched pathways. A) miR-133a-3p. 
B) miR-93-3p. C) miR-205-5p. The top ten most enriched pathways are presented for 
miR-133a and miR-205. There were only five enriched pathways for miR-93. The 
number of genes involved in the pathway are in brackets. Pathways are presented in 
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3.5 Validation of miRNA expression in plasma EVs 
 Patient cohort characteristics 
Four patients who donated their tissue to the biobank were identified as suitable for 
inclusion in this study. Two patients P29 and P56 had low-risk early EC and were 
treated with a TH-BSO. Two patients P95 and P121 received LNG-IUD treatment and 
following non-response to this treatment received a TH-BSO. The mean age of the 
patients who did not receive LNG-IUD treatment was 56.5±2.5 years old, and the mean 
BMI was 51.5±4.5. For the patients that did receive LNG-IUD treatment, the mean age 
was 44.5±1.5 years old and the mean BMI was 35±7.0. Patient clinicopathological 
characteristics are summarised in Table 11. 
Table 11: Clinicopathological characteristics of patient cohort  
 No LNG treatment No response 
P29 P56 P95 P121 
FIGO Stage Stage IA Stage IA Stage II Stage IIIA 
Grade Grade 1 Grade 1 Grade 1 Grade 3 
Histology Endometroid Endometroid Endometroid Endometroid 
Treatment TH + BSO TH + BSO 8 weeks LNG-IUD 
Then TH + BSO 
6 weeks LNG-IUD 
Then TH + BSO 
FIGO – International Federation of Gynecology and Obstetrics, TH + BSO – total hysterectomy with 
bilateral salpingo-oophorectomy 
  
 Validation of miRNA expression in plasma EVs through RT-
qPCR  
Expression of the candidate miRNAs was validated in plasma EVs derived from EC 
patients. In the no treatment group, miR-31 and miR-183 expression was not detectable 
(Ct > 35). All miRNAs were detectable in the no response group. The mean Ct values 
for each miRNA are presented in Table 12.  
  51 
 
Table 12: Ct values from RT-qPCR analysis of miRNAs in EVs from EC patients  
Gene No LNG treatment No response 
miR-25-5p 29.47±0.81 27.53±0.96 
miR-31-5p 36.81±2.09 32.20±0.16 
miR-93-5p 29.30±1.14 28.24±1.83 
miR-133a-3p 26.76±0.91 25.92±0.62 
miR-146b-3p 31.70±0.56 30.54±0.37 
miR-182-5p 30.83±1.48 27.96±1.04 
miR-183-5p 37.11±1.60 33.85±1.24 
miR-200b-3p 33.24±1.90 30.31±1.45 
miR-200c-3p 28.14±0.52 27.95±0.71 
miR-205-5p 28.82±0.58 27.44±0.66 
miR-1244 32.14±1.74 30.09±0.20 
let-7b-5p 27.28±0.70 25.84±0.66 
Values are presented as mean ± SD (n=2) 
 
The Ct values were normalised to endogenous reference gene expression, presented in 
Figure 14. None of the miRNAs investigated had statistically significant differences in 
normalised expression, as assessed by an unpaired t-test (p>0.05). However, miR-182 
expression was close to significance (p=0.069).  
 
  52 
 
 
Figure 14: Expression of candidate miRNAs in EVs from EC patient plasma. RT-qPCR 
was performed, and Ct values were normalised to miR-16 and miR-423 endogenous 
reference gene expression (ΔCt). The no LNG treatment group underwent hysterectomy 
as treatment for Stage IA Grade 1 EC. The no response group received LNG-IUD 
treatment but did not respond and subsequently received a hysterectomy. Expression of 
miR-31 and miR-183 was not detected in the no treatment group. Results are presented 
as the mean ± SD (n=2) with individual values plotted. Unpaired t-tests were performed 
to assess difference in normalised gene expression levels, with significance set at 
p<0.05. No statistically significant differences in expression were found. 
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 Discussion 
4.1 Key Findings 
This study was the first to look at EC EVs in the context of LNG resistance. The size, 
concentration, morphology and purity of EVs isolated from cell culture media of LNG 
resistant and sensitive cells were characterised through TRPS analysis, TEM and 
Western blots. Gene expression analysis found that many candidate miRNAs 
previously implicated in EC were not expressed in EVs or expressed at low levels that 
could not be detected with the sensitivity of our assay. No miRNAs investigated had 
significantly different expression between sensitive and resistant cell lines. However, 
high levels of biological variation in expression levels may have affected our ability to 
assess differential expression. Pathway enrichment analysis of miRNA target genes 
revealed that these miRNAs regulate genes that are involved in carcinogenic pathways 
and processes. Candidate EC miRNA biomarkers from the literature were expressed in 
EC patient plasma EVs. This study has demonstrated the viability of using a cell culture 
model to investigate EVs as biomarkers of LNG resistance in early EC. We have 
contributed valuable preliminary research into EV biomarkers of LNG resistance, and 
begun investigations into EV expression of miRNAs currently implicated in EC. 
 
4.2 Cellular proliferation in resistant cells is unaffected by 
LNG treatment 
The MFE296R and MFE319R cells used in this project are still resistant to LNG 
treatment, as demonstrated through evaluating cellular proliferation. While cellular 
proliferation in the resistant cells for both the MFE296 and MFE319 cell lines did 
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appear to be slightly lower than the corresponding sensitive cells, these differences 
were not statistically significant.  
The LNG resistant MFE296 and MFE319 cell lines were previously developed in our 
laboratory through continuous exposure of a subculture of cells to LNG, reaching a 
clinically relevant resistance to LNG (114). A second ‘sensitive’ subculture was 
passaged alongside resistant cell lines in DMSO as a control. As these cells had been 
stored prior to use in this project, continuing resistance to LNG treatment needed to be 
evaluated. Drug resistance can be lost both upon freeze-thaw and removal of the drug if 
the resistance was unstable (120). To best maintain the resistant phenotype throughout 
this project the cells continued to be cultured in drug treated media. As demonstrated 
through a proliferation assay, the resistant phenotype was maintained by the resistant 
cells making these cells lines suitable for this project. 
 
4.3 EV isolation from cell culture media and subsequent 
characterisation 
TRPS, TEM and Western blotting analyses fulfilled the EV characterisation 
requirements outlined in the MISEV 2018 guidelines (74). Subsequently, downstream 
analyses of molecular biomarkers can be correctly attributed to EVs.  
 Size exclusion chromatography as a method of isolating EVs 
In this study, SEC was the method selected for EV isolation. SEC has emerged as a 
popular choice for EV biomarker studies due to being time and cost efficient, while 
producing EV preparations of high yield and purity. The most widely used method of 
EV isolations continues to be ultracentrifugation (121), however UC is known to cause 
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damage to EV structure (122), generate EV aggregates (123), and has lower yield and 
increased non-vesicular contamination (124, 125). Therefore, this widely used 
methodology was not suitable for this study.  
Research on the optimal isolation method shows conflicting and contradictory results 
(124-127), which may be due to the varying EV sources used as the characteristics of 
each biofluid impacts on the efficacy of different methods (128). Currently, there is no 
gold-standard method of isolation, with the International Society of Extracellular 
Vesicles (ISEV) recommending that the downstream application of isolated EVs should 
inform the choice of isolation method (74). As this study was conducting gene 
expression analysis, yield and purity were the two critical factors. SEC is a quality 
isolation technique for RNA analysis due to the high EV specific miRNA and low non-
specific miRNA levels (129). Expression analysis of EVs is technically challenging as 
the amount of genetic material within EVs is low, and so yield must be high to 
maximise the material available for extraction. Because of the high purity and yield of 
SEC, this was the isolation technique employed for EV isolations in this study.  
Each EV isolation method captures distinct EV populations as the different isolation 
techniques will favour EVs of different size and density (130), resulting in bias that is 
carried throughout the study (131). This impacts on both RNA yield and downstream 
RNA profiling with different isolation techniques giving different enriched gene sets 
(132). Therefore, any results may be specific to the isolation method used, thereby 
limiting the value of any identified biomarkers (133). Guidelines for RNA analysis of 
EVs may be required in the future to ensure consistent and reproducible results (134). 
To strengthen the findings of this study an alternative isolation technique could be used 
to validate the gene expression results found and investigate any impact of the isolation 
methodology. However, for this exploratory cell culture model study the strengths of 
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SEC made this an ideal EV isolation technique. Future validation of candidate 
biomarkers identified should address this concern.  
 Single vesicle characterisation 
TRPS analysis demonstrated the particles in the EV preparations were of similar size 
and concentration between cell lines, and TEM provided high-resolution images of 
intact single EVs with double membranes. Together, TRPS and TEM analysis were two 
complementary techniques that fulfilled the single vesicle characterisation requirements 
as laid out in the MISEV2018 guidelines (74).  
 TRPS analysis of EVs 
TRPS analysis found a minimum EV size of between 130-150nm. TEM imaging 
showed the presence of particles smaller than expected, around 30nm in size. During 
TRPS, particle size is estimated based on the disruption to the current as the particle 
passes through the nanopore. The NP200 nanopore captures EVs sized 85-500nm, so 
cannot measure the small EVs seen in the TEM images. Multiple pores could be used in 
future studies to reduce the particle size bias introduced through the choice of nanopore 
size. The NP200 was selected for this study to best capture the range of EVs in the 
preparation. As smaller nanopores are easily blocked by larger particles, detecting 
particles of less than 100nm in diameter is technically challenging with current TRPS 
technology (135). Experimental parameters can introduce variation into the data when 
taking TRPS measurements. Variability between pores can influence the minimum 
particle size detected (136), and applying greater stretch reduces sensitivity to smaller 
particles but allows larger particles to be measured (135). Due to issues with the qNano 
Gold maintaining a steady current and the inherent heterogeneity of EV samples, 
setting adjustment is often unavoidable to achieve a steady flow of particles (137). 
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While the technical challenges of TRPS do impose limitations, this remains a quality 
method of single vesicle characterisation with highly accurate estimations of EV 
concentration and size (138, 139).  
Other commonly used alternatives to TRPS analysis include nanoparticle tracking 
analysis (NTA) and flow cytometry (FC). While a widely used method, NTA has a high 
level of statistical uncertainty and often underestimates the number of smaller particles 
(140). Conventional FC is only able to accurately measure larger EVs, typically around 
500nm in diameter (141), and requires highly specialised and customised equipment 
limiting accessibility of this method. Improvements to both NTA and FC are currently 
being developed to overcome the shortcomings of these methods (142-144). 
Quantifying small EVs remains a challenge for all methods currently available and may 
benefit the most from technological advancement.  
During TRPS measurement, any particle that causes a disruption to the current will be 
measured, which can lead contaminating particles to cause an overestimation of particle 
concentration. This highlights the importance of combining complementary techniques 
when characterising EVs to mitigate the limitations of each method. In this study, the 
TEM and subsequent Western blot analysis demonstrated pure EV preparations 
providing confidence in the accuracy of TRPS measurements. 
 TEM analysis of EVs 
TEM most accurately demonstrates EV size and morphology, and TEM showed the 
isolated particles in this study were intact vesicles with the characteristic EV 
morphology. Cryogenic transmission electron microscopy (cryo-TEM) avoids sample 
dehydration and best preserves EV morphology and size, making this the most suitable 
electron microscopy technique (145). Cryo-TEM was part of the initial study design of 
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this project but could not be completed due to the impact of Covid-19 on the 
availability of technical specialists, and negative stain TEM was carried out as an 
alternative. TEM provided strong evidence that the isolated particles were intact EVs.  
 Confirmation of EV specific proteins through Western blot  
The MISEV guidelines (74) outline three main categories of proteins that must be 
assessed to demonstrate the purity of the EVs (Table 13). Western blots confirmed the 
presence of the EV specific proteins TSG101 and CD9 in the EV preparations, and the 
absence of ApoB, a protein component of often co-isolated contaminating lipoproteins.  
Table 13: Protein categories analysed for EV characterisation 
Transmembrane protein Cytosolic protein Purity control 




Tests for commonly co-
isolated contaminants 
 
The observed bands for CD9 and TSG101 were close to the predicted sizes based on 
molecular weight, indicating their presence within the EV preparations. CD9 is a 
tetraspanin molecule enriched in EVs which may important for EV biogenesis (146), 
making CD9 a suitable transmembrane protein. TSG101 is part of the endosomal 
sorting complex required for transport (ESCRT) which traffics ubiquitinated proteins 
into endosomal membranes and facilitates multivesicular body formation (147). 
TSG101 is often enriched in EVs making it an ideal cytosolic protein marker.  
ApoB is a component of lipoproteins, which are commonly co-isolated with EVs. The 
two main isoforms of ApoB have different molecular weights, with ApoB-48 being 
210kDa, and ApoB-100 being 550kDa. No bands were observed at these sizes in the 
EVs for any of the cell lines, indicating the EV preparations were not contaminated 
with lipoproteins. The expected bands were observed in the plasma controls, as well as 
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a band at around 45kDa. ApoB is prone to degradation (148), with discrete fragments 
of ApoB of this size being observed previously (149). This degradation may also 
account for the other bands present between 100-210kDa that were observed in the 
plasma positive controls in some of the other blots.  
Taken together, these Western blot analyses confirm that the protocol used is isolating 
highly pure EVs, without non-EV contaminating particles.  
  EV isolation and characterisation in a clinical setting 
Of all the EV isolation methods, SEC is the most clinically transferable. Other common 
techniques such as UC are time consuming and require expensive specialist equipment. 
Precipitation-based isolation is attractive because of scalability, and short, 
straightforward protocols requiring only small amounts of starting sample, but these 
methods are plagued by high levels of contamination (150, 151). The ideal isolation 
methodology and subsequent standardisation of protocols are areas of ongoing debate 
surrounding clinical implementation of EV-based biomarkers. Salmond and Williams 
(152) suggest that standardised EV isolation methodology is not required as long as the 
isolated EVs are characterised thoroughly. However, isolation methodology impacts on 
downstream RNA profiling which suggests that some form of standardisation will be 
required (132). We believe that SEC best balances the requirements of purity and 
concentration. SEC protocols can be streamlined through use of automated fraction 
collectors and Amicon filters as in this study, making SEC more rapid than other 
techniques. Evaluating current evidence, our opinion is that SEC could be used 
clinically with further optimisation to improve scalability, allowing the implementation 
of EV biomarkers in a clinical setting.  
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Currently, characterisation of EVs must be carried out by a laboratory for each EV 
isolation protocol used (74). For clinical implementation of EV biomarkers, 
characterisation would therefore need to be carried out initially for each hospital 
laboratory. Sáenz-Cuesta et al. (153) suggest that data should be initially verified by a 
laboratory with EV expertise, as a quality control measure. We also suggest that routine 
validation should be required to retain accreditation, to maintain confidence in the 
quality of each laboratory’s isolation methodologies. Therefore, characterisation 
requirements should not hinder the clinical implementation of EV biomarkers.  
 
4.4 Expression analysis of candidate miRNA biomarkers 
 miR-16 and miR-423 as endogenous reference genes  
miR-16 and miR-423 had stable individual expression and a consistent geomean 
between resistant and sensitive cells in both cell lines, making these miRNAs suitable 
endogenous reference genes for this study. These two miRNAs were selected for use as 
reference genes based off previous use in the literature. miR-16 is widely used as a 
reference gene for miRNA expression analysis in EVs (154, 155), and has been used 
previously as an endogenous reference in EC EV studies (91). miR-423 is stably 
expressed in endometrial tissue (156), and has been used as an endogenous reference in 
EC cell line studies (157). miR-423 is also recommended as an endogenous reference 
by the manufacturers of the miRNA assay used in this study (Thermo Fisher, TaqMan 
Advanced miRNA assays). Reference genes are used to normalise gene expression, 
removing differences due to sample input. Thus, stable reference gene expression is 
critical for accurate expression profiles and to find true differences in gene expression. 
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Selecting appropriate reference genes for miRNA expression studies continues to be 
challenging, with no consensus on the most appropriate miRNA control genes in EC 
(158). Furthermore, there are no studies investigating the most stable reference 
miRNAs in EVs in EC. ISEV have indicated that cellular miRNA endogenous controls 
cannot be assumed to be suitable for EV studies due to the selective packaging of 
miRNAs into EVs (159). For this exploratory, in vitro study, widely used miRNA 
controls such as miR-16 and miR-423 were appropriate. However, investigating and 
validating EV EC miRNA controls must be prioritised by the EC field, as quality 
endogenous controls will be a requirement for clinical biomarker use, and will also 
ensure the relevance and reproducibility of preclinical studies.  
 Some candidate miRNA biomarkers are not expressed in EVs 
from MFE296 and MFE319 cell lines 
Of the candidate miRNAs investigated, four of the twelve (miR-31, 146b, 183 and 
200b) had no measurable expression in any of the cell lines. A further three miRNAs 
(miR-93, 133a and 205) had expression detected in only one of the cell lines.  
The miRNAs investigated were chosen from the literature based on their previously 
demonstrated relevance to EC, so were hypothesised to be expressed in EVs in the EC 
cell lines. miRNAs 146b (115), 183 (160) and 200b (161) have been found to be 
upregulated in EC compared to healthy tissue. miR-31 has discordant expression levels, 
with studies finding miR-31 both upregulated (162, 163) and downregulated in EC 
tissue compared to healthy controls (164). All these studies look at tissue miRNA 
expression, and so the difference in expression patterns observed in this study may be 
due to different expression in the cell lines, or these miRNAs may be expressed locally 
in tumour tissue but not packaged into EVs. In EVs, miR-200b, miR-146b and miR-31 
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are downregulated in EC cases compared to controls (98, 102). These miRNAs may be 
downregulated in both the EC cell lines used in this study, resulting in the lack of 
detectable expression in EVs.  
The difference in expression between EC EVs and tissue is an interesting and important 
result. Tumour cells selectively package miRNAs into EVs for release into circulation 
to influence distant cell types (106), resulting in EV and parent cell miRNAs showing 
different expression patterns (165). The differences between miRNA expression in 
tissue and EVs may be able to provide insight into which miRNAs are regulating 
processes locally within the tumour, and which miRNAs are important for mediating 
more distal effects.  
 Impact of the tumour microenvironment on EV miRNA expression 
EVs are a novel target for biomarker research due to their role in cell communication. 
miRNAs from tumour-derived EVs influence surrounding cells such as macrophages, 
and the reverse also occurs with non-malignant cells modifying tumour cells, both 
contributing to cancer progression (166, 167). Evidence from cell culture models 
suggest that these interactions within the TME may significantly influence the miRNA 
profiles of EVs. EV miRNAs from 2D cell culture models have lower correlation with 
human plasma EVs (80%), while 3D models had 96% similarity between EV miRNAs 
(165). A 2D cell culture model was an appropriate place to begin investigations because 
the homogeneity allows genetic differences identified to be attributed to providing LNG 
resistance. However, the simplicity of the cell culture model may influence EV 
packaging, resulting in a lack of expression of miRNAs that were hypothesised to be 
expressed based on tissue and plasma EV miRNA expression. 
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 Impact of RNA yield on detecting EV miRNA expression 
Another major factor that may have contributed to the lack of detectable expression of 
candidate miRNAs was a low RNA yield. The endogenous reference genes, along with 
miRNAs miR-25, miR-1244 and let-7b, had strong expression demonstrating there was 
enough RNA to detect highly expressed miRNAs. However, many miRNAs with 
detectable expression had high Ct values, suggesting that most of the candidate EC 
miRNAs are only expressed at low levels in EVs, if they are expressed at all. This low 
expression is difficult to detect and resulted in high levels of biological variation in the 
ΔCt values, reducing the statistical power to detect differential expression. The inability 
to consistently detect expression of these candidate miRNAs suggests their expression 
may be too low in EVs for use as EC biomarkers. Previous investigations into EC EV 
miRNAs have used less clinically accessible methods of detecting expression, such as 
RNA sequencing and microarray panels (98, 102). Further research is required to 
identify EV miRNAs that are highly expressed and can be consistently detected using 
clinically relevant assays, such as the RT-qPCR assay used in this study.  
Low RNA yield is challenging to overcome as the EV concentrations yielded from 
culture media are low, with many factors contributing to the overall EV yield. For 
example, cells become quiescent at high confluency, reducing EV secretions (168). 
Confluency is also only an estimate, making this a difficult parameter to keep constant. 
The impact of biological factors on EV yield were minimised by keeping conditions 
across cell passages and cell lines as consistent as possible. However, these factors still 
may have contributed to variation in EVs isolated and RNA extracted, contributing to 
the biological variation in gene expression observed. 
Technical factors also influence the resulting EV yield too. The cell culture flask limits 
the number of cells that can be cultured, making EVs dilute in the harvested media. As 
  64 
 
the SEC isolation method chosen in this study has a sample processing limit of 10mL, 
increasing the number of flasks does not solve this issue. As SEC has a high EV yield, 
the sample processing limitation of SEC was thought to be overcome by the inherent 
efficiency of the isolation methodology. Even for the most highly expressed miRNAs, 
there may be on average less than one copy of a given miRNA molecular per vesicle 
(169). Therefore, there may simply be insufficient EVs in cell culture media to be able 
to quantify miRNAs with low expression. 
 miR-133a as an EC and LNG resistance biomarker 
This study found miR-133a was downregulated in resistant cells compared to sensitive 
cells in the MFE319 cell line. Pathway enrichment analysis highlighted the tumour 
suppressive role of miR-133a, with enriched pathways involved in cancer progression.  
Because of the tumour suppressive role, miR-133a has been investigated as a biomarker 
in multiple other cancers, with downregulation associated with poorer prognosis (170-
172). In EC, miR-133a is also downregulated in tumour tissue compared to normal 
endometrial tissue (163). Expression of miR-133a has been detected in culture media 
EVs from Ishikawa and HEC-1A EC cell lines (101), but differential expression in EVs 
has not yet been investigated, nor expression in EVs from clinical samples.   
In epithelial endometrial cells, progesterone induces miR-133a expression which in turn 
inhibits cell proliferation (173). This suggests that upregulation of miR-133a may be a 
mechanism for the inhibitory effect progesterone has on cellular proliferation in the 
endometrium. The MFE319R cells in this study had lower miR-133a levels so 
upregulation in the presence of LNG is seemingly not occurring. This may be what is 
allowing the resistant cells to continue to proliferate even in the presence of LNG.  
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Current evidence suggests that miR-133a is regulated by progesterone through PR-B 
(173), and that progesterone dependent transcriptional activation is mediated through 
this receptor isoform (174). Studies investigating PR as a biomarker have found that 
expression levels are predictive of LNG-IUD response, but low sensitivity and 
specificity prevents clinical use (64). PR-B specifically may therefore be a more 
informative biomarker rather than broadly measuring all PR expression, as it appears 
PR-B is the isoform important for inhibiting cellular proliferation. A very recent study 
found that while PR-B could not predict whether a patient would respond to LNG-IUD 
treatment, weak stromal PR-B expression could predict LNG-IUD non-response and 
recurrence with 100% sensitivity (175). Combining PR-B with other biomarkers that 
stratify non-response risk may allow for accurate prediction of LNG-IUD treatment 
response. Further research is required to investigate miR-133a expression before miR-
133a can contribute to LNG-IUD resistance risk prediction.  
Hypoxia-inducible factor 1 (HIF-1) signalling was the most significantly enriched 
pathway of miR-133a target genes, so may be more active in the resistant cells which 
had downregulated miR-133a expression. HIF-1 signalling has been shown to 
contribute to cancer progression through upregulating genes involved in apoptosis 
resistance, angiogenesis and metastasis (176-178). In EC, increased HIF-1 signalling 
has been associated with higher stage cancers and increased mortality (176, 179, 180).  
HIF-1 signalling may be influenced by progesterone, with MPA decreasing signalling 
in breast and ovarian tissue (181, 182). In endometrial tissue HIF-1α is decreased when 
progesterone is high, and levels highest at progesterone withdrawal (183, 184). miR-
133a may be the mechanism in which progesterone reduces activity of HIF-1 
signalling.  
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In normal endometrial tissue, miR-133a is upregulated by progesterone (173, 185). Our 
pathway enrichment analysis and the observed decrease in signalling in response to 
progesterone suggest that this upregulation of miR-133a may cause a decrease in HIF-1 
signalling. In normal endometrial tissue, progesterone induced miR-133a expression 
may maintain tissue homeostasis by preventing excess HIF-1 signalling, preventing the 
activation of oncogenic pathways. As miR-133a is usually downregulated in EC (163), 
LNG may treat EC by inducing upregulation of miR-133a and subsequently inhibiting 
HIF-1 signalling. In the LNG resistant cells, the progesterone dependent increase in 
miR-133a does not seem to be occurring with miR-133a downregulated in the 
MFE319R cells. This suggests that miR-133a expression in response to progestin may 
be dysregulated in the resistant cells. The regulation of miR-133a in response to 
progesterone may therefore be an important factor in LNG resistance, as proposed in 
Figure 15. Progesterone dependent expression of miR-133a and subsequent HIF-1 
signalling in endometrial tissue specifically warrants further research. 
 
Figure 15: Proposed mechanism of miR-133a contributing to LNG resistance. 
Progesterone upregulates miR-133a expression in normal endometrial tissue, inhibiting 
HIF-1 signalling preventing the activation of oncogenic processes. miR-133a is 
downregulated in endometrial cancer, likely due to progesterone imbalance, activating 
HIF-1 signalling. LNG treatment induces miR-133a expression, inhibiting HIF-1 
signalling. LNG resistant endometrial cells no longer upregulate miR-133a in response 
to progestin, allowing HIF-1 signalling to activate angiogenesis, apoptosis resistance 
and metastasis pathways. EC – endometrial cancer, HIF-1 – hypoxia-inducible factor 1, 
LNG – levonorgestrel.  Made using BioRender.  
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 miR-93 as an EC and LNG resistance biomarker 
miR-93 was downregulated in the MFE296R cell line compared to the sensitive cells, 
with no detectable expression in the resistant cell line.  
miR-93 appears to have both oncogenic and tumour suppressive roles, with miR-93 
inhibiting migration, invasion and proliferation in ovarian and breast cancer (186, 187), 
while promoting epithelial to mesenchymal transition (EMT) in EC (188). Most 
evidence supports miR-93 having a oncogenic role in EC, increasing migration and 
tumour invasiveness (189, 190). In EVs, high miR-93 expression predicted lower 
overall survival and more aggressive tumours in EC (91). The opposite was found in 
whole serum, with low miR-93 found in EC cases, and downregulation was associated 
with poorer survival outcomes (191). Discordance between these studies may be due to 
the use of serum miRNAs compared to EVs. The difference in EV miR-93 expression 
between Zheng et al. (91) and the current study could also be attributable to the 
different EV isolation technique used. The different isolation methods capture distinct 
EV populations, impacting on RNA yield and downstream RNA profiling (131, 132). 
The conflict between results suggests that miR-93 needs further investigation before 
this miRNA can be used as an EC biomarker. This also highlights the difficulties with 
EV biomarker research, as without standardised protocols there are many experimental 
design factors which may be influencing results found.  
Pathway enrichment analysis found that miR-93 target genes are involved in cell 
adhesion, suggesting that increased miR-93 decreases adhesion and can lead to cells 
gaining the ability to migrate and invade. miR-93 expression is involved in EMT, with 
miR-93 downregulating E-cadherin expression and upregulating N-cadherin expression 
in EC cells (188). The resistant cells used in this study have decreased adhesive ability 
compared to the sensitive cells (114). Therefore, the downregulation of miR-93 in the 
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MFE296R EVs is surprising, and not what would be expected based on current 
literature. miR-93 may be regulating pathways not currently reported in the literature, 
and the downregulation in these cells may therefore be related to LNG resistance.  
Thus far, miR-93 has not been investigated regarding progesterone resistance in EC. In 
breast cancer, EV miR-93 levels are predictive of PR status (192) with higher miR-93 
levels in PR and ER negative breast cancer (193). This suggests there may be a 
relationship between EV miR-93 levels and steroid hormone receptor expression. 
Investigations into miR-93 and hormone receptor levels in EC are required to see if this 
relationship is also present in EC.  
Further research is required to explore the protein expression patterns of the 
downstream targets of miR-93. This may elucidate how the downregulation of miR-93 
may contribute to the LNG resistance phenotype, and identify pathways involved in 
providing the resistance.  
 miR-205 as an EC and LNG resistance biomarker  
In this study, expression of miR-205 was downregulated in the resistant cells compared 
to the sensitive cells in the MFE319 cell line.  
miR-205 has found to be upregulated in EC compared to normal endometrial tissue in 
multiple studies (160, 194, 195). miR-205 is known to be an oncogenic miRNA, with 
tumour suppressors such as phosphatase and tensin homolog (PTEN) as target genes 
(196). However, Zheng et al. (91) found EV expression of miR-205 was downregulated 
in cases compared to controls. Therefore, the expression of miR-205 appears to differ 
between tissue and EVs. This suggests the role of miR-205 may be important locally 
within the tumour tissue, and less involved in distal effects so is not packaged into EVs 
at a high rate in EC.   
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The effect of miR-205 varies between tissue types, acting as an oncogene in some 
cancers while a tumour suppressor in others (197, 198). The varied effect of increased 
miR-205 has also been observed within EC literature, being associated with increased 
and decreased overall survival (194, 195), while Dong et al. (199) found no association. 
This discordance within EC literature and the differing effects within different cancer 
types suggests miR-205 action may be dependent on other molecular factors not yet 
well understood. The use of heterogenous EC patient populations makes comparing 
studies challenging and may impact on the result found. Therefore, miR-205 may not 
be appropriate for use as a single EC biomarker and may be more informative of EC 
diagnosis and prognosis when combined with other biomarkers.  
miR-205 can regulate cell proliferation through targeting oestrogen related receptor 
gamma (ERRγ). Inhibition of miR-205 in EC cells results in increased ERRγ, leading to 
the suppression of cell proliferation, migration and invasion (200). However, the effect 
ERRγ has on ER regulated transcriptional activity depends on receptor presence. In 
ERα positive EC cells, ERRγ overexpression results in repression of oestrogen response 
element (ERE) transcriptional activity, reducing cell proliferation, while the opposite is 
seen in ERα negative cells (201). This suggests that the downstream impact miR-205 
expression is dependent on ERα status. Downregulated miR-205 leads to increased 
ERRγ, which in ERα positive cells suppresses cell proliferation, while in ERα negative 
cells promotes proliferation (Figure 16). Thus, downregulation of miR-205 is 
oncogenic in ERα negative cells, while tumour suppressive in ERα positive cells. ERα 
status has been associated with overall survival and has been proposed as a prognostic 
biomarker of EC (202). However, ER status alone is insufficient for prognostic 
predictions in all EC patients (203). The combination of ERα status and miR-205 
expression may better stratify patient risk, and form part of a panel of EC biomarkers. 
  70 
 
Further research into miR-205 expression and ERα status should be conducted to see 
whether the same effect on cell proliferation is observed in vivo. Also, studies into the 
association between miR-205 and ERα expression should evaluate their potential as a 
combined biomarker.  
 
Figure 16: Effect of decreased miR-205 in endometrial cancer cells depends on ERα 
status. miR-205 targets ERRγ, so when miR-205 levels are decreased, ERRγ levels 
increase. ERRγ inhibits transcriptional activity from oestreogen response elements 
(ERE) in ERα positive cells, decreasing cell proliferation. ERRγ activates ERE 
transcriptional activity in ERα negative cells, stimulating cell proliferation in ERα 
negative cells. ERRγ: oestrogen related receptor gamma. ERα: oestrogen receptor 
alpha. Made using BioRender. 
 
Hippo signalling was an enriched pathway of miR-205 target genes. When dysregulated 
in cancer, aberrant Hippo signalling results promotes cell proliferation and EMT (204). 
Hippo signalling is important in many uterine pathologies such as endometriosis (205), 
but investigation into the role of this signalling pathway in EC is limited thus far. 
Regulator of the Hippo signalling pathway Yes-associated protein (YAP) has been 
found to upregulated in EC (206). YAP is a target of miR-205, so the loss of miR-205 in 
the resistant cells could result in increased Hippo signalling and greater activity of this 
oncogenic pathway. Hippo signalling is activated by oestrogen (207), so may contribute 
to the development of EC and warrants further investigations in EC.   
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Little is known about the relationship between miR-205 and progesterone. One study 
found increased miR-205 levels were associated with higher PR expression in EC 
(199). The authors also hypothesise that PR may act as a transcription factor to regulate 
miR-205 expression, due to the PR binding sites upstream of the miR-205 gene. A 
progestin resistant Ishikawa cell line had increased miR-205 expression in the resistant 
cells compared to sensitive cells, contradictory to findings from this study (208). This 
may attributable to the varied effect of miR-205 dependent on other genetic differences 
between the cell types. While Ishikawa, MFE296 and MFE319 cell lines are all 
considered to be type I EC cells, there are many molecular differences between the cell 
lines. Ishikawa cells express ERα, ERβ and PR at high levels, while MFE296 and 
MFE319 express low levels of ERs (209). The genetic differences between cell lines 
may mean that even though miR-205 is expressed differently between the resistant 
cells, the miR-205 expression pattern may contribute to the LNG resistance phenotype 
in both cell types. Future studies should investigate the relationship between 
progesterone and miR-205 expression. Research is also required into the downstream 
gene targets of miR-205 to explore how miR-205 can contribute to LNG resistance 
when both downregulated and upregulated.  
 
4.5 Candidate miRNA biomarkers are expressed in EC 
patient plasma EVs 
Expression of the candidate miRNAs was higher in the plasma EVs than in the cell 
culture media EVs, with all miRNAs detected in the no response group, and only two 
miRNAs miR-31 and miR-183 were undetectable in the no treatment group.  
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This result supports our hypothesis. As the miRNAs chosen are candidate biomarkers 
of EC and many have been reported as expressed in EC EVs (91, 98), we expected to 
see expression in EC patient plasma EVs.  
The lack of DEGs between the no treatment and no response groups is unsurprising, as 
the small cohort limited the ability to detect statistically significant differences in 
miRNA expression. However, on visual inspection of the results there are miRNAs that 
warrant further research in larger cohorts, particularly miR-182 which was close to 
significance (p=0.069). With a larger cohort, differences in expression of the miRNAs 
may be identified.   
The patient cohort used may also limit the ability to detect differences. The difference 
in FIGO stage of the cancers may confound the results, along with the inability to 
assess whether the no treatment group are responsive to LNG treatment. The main 
objective of the patient plasma EV gene expression analysis was to confirm that these 
miRNAs are expressed in patient EVs, as very little research into EC EVs has been 
conducted so far. Many miRNA studies into EC EV expression thus far have used 
clinically inaccessible methods such as to identify candidate miRNAs (98, 102). 
Validation of the expression of these miRNAs is required to ensure that expression can 
be detected with clinically accessible assays such as PCR. This study fulfilled the 
objective of demonstrating that candidate miRNA biomarkers from the literature are 
expressed in plasma EVs at levels that are easily detectable. A larger study into EV 
miRNA expression in LNG treatment response using EC patient plasma has been 
started by a PhD student in our lab. This study acted as a proof of concept that these 
candidate miRNAs can be detected in EC patient plasma EVs, forming the foundation 
for ongoing research in our laboratory and the EC EV field.  
  73 
 
Many candidate miRNAs had detectable expression in plasma EVs but not in media 
EVs, which may be because EVs are more abundant in plasma resulting in higher RNA 
concentrations (210). However, the EVs isolated from plasma are not necessarily from 
the tumour cells, or oncogenic in nature. While tumour cells secrete more EVs than 
non-malignant cells (211), plasma will contain EVs from many other cell types creating 
biological noise. Currently, we are unable to distinguish EVs derived from tumour 
tissue from other vesicles in plasma (212), although detection of proteins specific to 
tumour-derived EVs may allow this to change in the future (213). Our cell culture 
model does not suffer from this limitation the way that clinical samples such as plasma 
do. The media EVs are only derived from the EC cell lines present in the flask. Since 
the candidate miRNAs were expressed at such low levels in the cell culture model, this 
begs the question how specific to EC these candidate miRNAs are. The lack of 
expression in media EVs may not be caused by low EV yield, and instead due these 
miRNAs being expressed at low levels in these cell types, or EC cells in general. This 
suggests that the candidate miRNAs currently in the literature need to be studied for 
their specificity to EC. This also highlights the strength of starting with a simple in-
vitro model of EC for biomarker discovery, as it avoids many of the confounding 
factors associated with more complex models or clinical samples. While 2D cell culture 
models have their own limitations, we can be confident the EVs isolated are from EC 
cells.  
 
4.6 Limitations of RT-qPCR assay 
The expression of some candidate miRNAs was too low to be detected with the 
sensitivity of the RT-qPCR assay. As previously discussed, low RNA yield is a 
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challenge with cell culture EV studies. To improve yield, EVs can be isolated from two 
media samples from the same cell culture passage and pool the EVs for RNA 
extraction. Due to the time constraints in an Honours project this was not achievable. 
The resulting RNA concentration was low, and this may have contributed to the 
inability to detect the candidate miRNAs.  
miRNA expression showed large amounts of variation between biological replicates, 
making detecting statistically significant differences difficult. It was assumed that the 
starting input of RNA would be similar in all samples due to the use of the same 
protocol. However, many factors could affect the starting levels of RNA, including 
RNA extraction efficiency and EV yield. TRPS analysis showed that EV concentration 
did vary between biological replicates, but variation did not appear to be too large. 
However, EV concentration does not necessarily correlate to RNA concentrations 
(153). Therefore, similarity in EV concentration does not ensure similar RNA 
concentrations, possibly contributing to the variation observed within biological 
replicates.  
 
4.7 Limitations of pathway enrichment analysis 
The ability to identify pathways of downstream targets of miRNAs is limited by our 
current knowledge of verified miRNA target interactions. As miRNAs have been most 
heavily studied in cancer thus far, this has resulted in verified gene targets being biased 
to cancer and cancer related processes. This bias has been demonstrated by Godard et 
al. (214) who used miRTarBase to generate a list of all the genes that are targeted by at 
least one miRNA. This gene list had enriched pathways relating to mostly cancer and 
the cell cycle. Additionally, when compared to the enriched pathways of the target 
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genes of one miRNA, most of the enriched pathways were common to both gene lists. 
This reduces the confidence that these pathways are specifically regulated by the 
miRNA under investigation. These types of in silico investigations may need to be 
repeated in the future, when our understanding of miRNA target gene interactions has 
expanded to a wider range of processes and diseases, and the bias to cancer pathways 
has been reduced.  
 
4.8 Future directions 
EV research is challenging due to lack of standardised protocols, difficulties with yield, 
and the natural variability of EV content and secretion, as previously discussed. Yet, 
EVs remain a popular research topic in the literature and particularly in the field of 
cancer biomarker research due to their important role in disease. EV researchers now 
need to overcome the issue of translating the findings from in-vitro and pre-clinical 
studies into clinically relevant tests that will benefit patients. EV isolation and 
characterisation technology advancement may allow for the use of EV biomarkers 
clinically. The translatability of research will also benefit from increased 
standardisation of protocols used in EV studies and should be a priority for the field.  
The initial design for this study was to first complete small RNA sequencing on culture 
media EV RNA to identify DEGs and to validate expression using RT-qPCR. However, 
due to factors outside the researcher’s control, sequencing was unable to be carried out. 
Instead, candidate miRNAs were selected from the literature. The limited 
understanding of the mechanisms of progesterone resistance means a candidate gene 
approach may not be most appropriate for discovering miRNA biomarkers. A 
discovery-based approach holds greater potential to identify novel resistance 
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biomarkers and to identify pathways that may contribute to the resistant phenotype. 
RNA isolated from EVs during this project was stored for RNA sequencing. Thus, a 
logical next step is to complete library prep and to undertake RNA sequencing.  
Cell culture models of cancer do not closely resemble in vivo tumours, as the 2D model 
lacks the cellular interactions with the extra-cellular matrix (ECM) and other cells TME 
cells such as immune cells. As discussed previously, this may be impacting the 
expression of the EV biomarkers from this model. Our laboratory is currently 
developing an ex-vivo model of EC. Cell culture media from these models could be 
harvested and used for EV isolation, to test our candidate miRNA markers. The EVs 
would be EC derived, thus maintaining specificity for EC while better modelling 
tumour complexity than 2D cell culture models. This would avoid confounding vesicles 
present in clinical samples but provide increased biological relevance, so would be an 
excellent opportunity to continue research into the miRNAs investigated in this study.  
 
4.9 Clinical implications 
This study has demonstrated that the current candidate miRNAs for EC biomarkers 
may not be specific to early EC tumour cells due to the low levels of expression within 
the EVs isolated from our cell culture model. This suggests more research is required to 
identify EC specific markers, as non-specificity may reduce the accuracy the 
biomarker. We also suggest that a miRNA panel rather than a single biomarker may be 
more effective for LNG treatment monitoring, which has been found to be the case with 
diagnostic EV miRNAs biomarkers (102). A combination of of EC EV miRNAs may 
overcome the issue of single miRNA non-specificity. As miRNAs can regulate 
numerous pathways with tissue specific effects that depend on underlying genetic 
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factors, a single biomarker is unlikely to be predictive of complex disease and 
processes such as cancer and drug resistance. With many possible mechanisms of drug 
resistance, our candidate miRNAs may not be dysregulated in all LNG resistant ECs. 
Thus, integrating these proposed biomarkers into a larger panel for further testing may 
increase the predictive ability and clinical utility of miR-93, miR-133a and miR-205.   
A blood-based biomarker test of LNG response aims to widen access to LNG-IUD 
treatment for early EC treatment. Current commonly investigated tissue biomarkers 
thus far have lacked the required sensitivity and specificity for clinical use (64). 
Meanwhile, genetic information has shown promise for being more predictive of 
response, with early studies suggesting molecular subtyping may be predictive of LNG-
IUD response and progression (215, 216). However, the cost of the DNA sequencing 
required to assess the POLE subtype means molecular subtyping of EC patients has not 
become routine clinical practice in Aotearoa (217). Therefore, in Aotearoa there are 
limitations to the extent in which EC treatment is currently personalised. Blood-based 
biomarkers may be a more accessible method of incorporating patient specific 
molecular information to personalise treatment. Biomarker testing could require only a 
PCR test, thus is feasible for implementation within our healthcare system. 
Personalising EC treatment using predictive biomarkers would allow for the LNG-IUD 
to be prescribed more safely, with increased confidence that the patient will respond to 
treatment. Blood-based biomarkers could allow blood tests to replace pipelle biopsies, 
making ongoing monitoring more comfortable and accessible. This would enable wider 
access to LNG-IUD treatment, allowing clinicians to offer this treatment to any patient 
who wishes to avoid hysterectomy.  
Developing a biomarker test in Aotearoa maintains the translatability of the results to 
our EC patient population. The ongoing research in our lab involves measuring blood-
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based miRNA biomarkers within EVs throughout LNG-IUD treatment of EC patients 
in Aotearoa. Therefore, the results will be translatable and relevant to our EC patient 
population, with the ability to prioritise the Māori and Pasifika women. Any subsequent 
biomarker tests developed from this research would have shorter clinical 
implementation times, as opposed to tests developed overseas that need to be evaluated 
for use in our populations. Thus, the results from this study and wider research in our 
lab aim to directly benefit women in Aotearoa by investigating translatable predictive 
biomarkers relevant to our EC patient population.  
 
4.10 Conclusions 
Demand for LNG-IUD treatment will likely only continue to grow, with rising rates of 
obesity and increasing incidence of EC in premenopausal women. Thus, research into 
biomarkers of treatment response is critical for making this treatment safer and making 
access equitable for all women in Aotearoa.  
This study has investigated many of the current candidate EC miRNA biomarkers in 
EVs of an LNG resistant cell culture model and validated expression with patient 
plasma EVs. This study highlighted the challenges of working with EVs, but also 
demonstrated their potential to provide novel insights into the pathways dysregulated in 
disease. Further research into the miRNAs identified in this study is required to better 
understand their role in EC and LNG treatment resistance. We have highlighted many 
areas of interest for future investigations of current candidate EC miRNAs. This was 
the first study to investigate EC EV miRNA biomarkers in LNG treatment resistance, 
providing the foundation for future studies to work from.  
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Appendices 
Appendix 1: TRPS analysis of EV size  
Figure S1: Size distribution histogram of EVs isolated from cell culture media. 
Concentration (particles/mL) is plotted against size (nm). A-C) MFE296R. D-F) 
MFE296S. G-I) MFE319R. J-L) MFE319S.  
A B C 
F D E 
G H I 
J K L 
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Appendix 2: Western blot analysis of EV specific proteins 
   
 
Figure S2: TSG101 detection in EV lysate through Western blotting. TSG101 
molecular weight: 43kDa. Observed band size: 50kDa. Protein detection carried out in 
biological triplicate.  
  
 




Figure S3: CD9 detection in EV lysate through Western blotting. CD9 molecular 
weight: 24kDa. Observed band size of 27kDa. Protein detection carried out in 
biological triplicate. 




Figure S4: Apolipoprotein B detection in EVs and plasma controls through Western 
blotting. Molecular weight: 210kDa. Some observed bands at 13kDa in EV lysates. 
Observed bands at 45kDa and 100kDa-260kDa in plasma controls. Protein detection 
carried out in biological triplicate. 
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Appendix 3: Gene expression analysis using RT-qPCR  
Table S1: Raw RT-qPCR Ct values for MFE296 cell lines 
 MFE296S MFE296R 
miRNA of 
interest 
N1 N2 N3 Mean N1 N2 N3 Mean 
let-7b 21.25 26.37 25.04 24.22 23.61 30.70 30.66 28.31 
miR-25-5p 25.51 30.27 26.80 27.53 26.61 26.80 28.41 27.27 
miR-31-5p 40.00 40.00 39.46 39.82 40.00 40.00 40.00 40.00 
miR-93-3p 28.46 33.77 35.63 32.62 37.79 37.78 40.00 38.93 
miR-133a-3p 36.44 38.93 38.66 38.01 40.00 36.43 40.00 38.81 
miR-146b-3p 40.00 40.00 40.00 40.00 37.79 37.38 40.00 38.70 
miR-182-5p 24.87 31.37 33.36 29.87 38.23 31.03 36.31 35.19 
miR-183-5p 35.81 31.77 40.00 35.86 40.00 36.79 40.00 38.93 
miR-200b-3p 39.40 40.00 32.85 37.42 40.00 36.77 40.00 38.92 
miR-200c-3p 35.20 36.28 38.64 36.70 38.74 32.98 32.78 34.83 
miR-205-5p 40.00 40.00 40.00 40.00 40.00 40.00 36.29 38.76 
miR-1244 20.98 25.87 24.42 23.76 22.86 24.68 30.27 25.93 
Candidate reference genes 
miR-16-5p 22.55 30.70 25.74 26.33 28.43 26.72 29.90 28.35 
miR-186-5p 25.15 37.34 29.61 30.70 34.73 29.53 32.12 32.13 
miR-423-5p 22.66 27.40 24.52 24.86 23.19 23.16 29.48 25.27 
miR-520d-5p 40.00 38.16 40.00 39.39 40.00 38.16 37.86 38.67 
N = mean of technical triplicate Ct values for each biological replicate.  
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Table S2: Raw RT-qPCR Ct values for MFE319 cell lines  
 MFE319S MFE319R 
miRNA of 
interest 
N1 N2 N3 Mean N1 N2 N3 Mean 
let-7b 28.46 30.34 27.63 28.81 27.85 26.56 28.64 27.68 
miR-25-5p 27.50 28.06 28.65 28.07 28.16 28.63 25.90 27.56 
miR-31-5p 40.00 39.87 34.48 38.12 40.00 40.00 40.00 40.00 
miR-93-5p 39.04 39.51 37.99 38.85 35.60 32.94 38.41 35.65 
miR-133a-3p 34.05 24.40 31.58 30.01 40.00 36.67 34.10 36.92 
miR-146b-3p 40.00 31.44 36.41 35.95 40.00 40.00 36.34 38.78 
miR-182-5p 36.67 30.30 27.94 31.64 39.93 30.81 28.84 33.19 
miR-183-5p 39.71 33.69 36.87 36.76 40.00 40.00 36.60 38.30 
miR-200b-3p 33.25 30.27 34.17 32.56 40.00 34.65 34.80 38.27 
miR-200c-3p 32.38 29.64 28.37 30.13 35.40 38.61 27.99 34.00 
miR-205-5p 25.62 29.80 27.90 27.77 40.00 40.00 30.11 36.70 
miR-1244 22.42 26.43 24.38 24.41 26.82 25.72 22.67 25.07 
Candidate reference genes 
miR-16-5p 28.29 28.49 25.99 27.59 30.60 25.12 25.91 27.21 
miR-186-5p 31.81 31.61 28.89 30.77 37.33 29.53 28.57 31.81 
miR-423-5p 27.15 24.50 23.93 25.81 28.03 24.25 25.16 26.76 
miR-520d-5p 34.56 40.00 37.18 37.25 40.00 40.00 35.53 38.51 
N = mean of technical triplicate Ct values for each biological replicate.  
Mean = mean Ct value of biological replicates. 
 
 
Table S3: Ct values of candidate endogenous reference genes 
 MFE296R MFE296S MFE319R MFE319S 
miR-186 32.13±2.12 30.70±5.04 31.81±3.92 30.77±1.33 
miR-520d 38.67±0.98 39.39±1.67 38.51±1.67 37.25±2.22 
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Table S4: Raw RT-qPCR Ct values for patient plasma EVs 
 No treatment No response 
miRNA of 
interest 
P29 P56 Mean P95 P121 Mean 
let-7b 26.58 27.98 27.28 25.18 26.50 25.84 
miR-25-5p 28.66 30.29 29.47 26.58 28.49 27.53 
miR-31-5p 34.73 38.90 36.81 32.04 32.36 32.20 
miR-93-5p 28.16 30.45 29.30 26.41 30.06 28.24 
miR-133a-3p 25.85 27.67 26.76 25.30 26.54 25.92 
miR-146b-3p 32.26 31.15 31.70 30.18 30.91 30.54 
miR-182-5p 29.36 32.31 30.83 26.92 29.00 27.96 
miR-183-5p 35.52 38.71 37.11 35.09 32.62 33.85 
miR-200b-3p 31.34 35.14 33.24 28.86 31.75 30.31 
miR-200c-3p 27.62 28.65 28.14 27.24 28.66 27.95 
miR-205-5p 28.24 29.40 28.82 26.78 28.10 27.44 
miR-1244 30.40 33.88 32.14 29.89 30.30 30.09 
Reference genes 
miR-16-5p 18.51 20.99 19.75 17.22 19.60 18.41 
miR-423-5p 22.02 23.66 22.84 20.59 23.14 21.86 
Mean of technical triplicate Ct values for each sample is presented.  
Mean = mean Ct value of group replicates. 
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Appendix 4: Pathway enrichment analysis 
Table S5: Gene targets of miR-133a-3p from MiRTarBase 
CDC42 FAM120C SP1 CDKN1A TMEM59 ZMAT4 SERPINH1 
HCN4 BCAN NR4A2 MC2R PIGR PTMA PIAS2 
UCP2 TCTEX1D2 BCL2L1 SESN3 SFTPB C11orf24 POU2F2 
KRT7 ARL6IP1 MCL1 RHOQ PER2 NCDN SEPT6 
CACNA1C RFT1 RNF103-
CHMP3 
HIST2H2AC TXNRD3NB CCDC39 APOL6 
HCN2 SENP1 IGF1R DCAKD CCNI ITPKB CMTM4 
PKM SMIM14 FAM160B1 THBS2 IP6K1 TPM3 TRIM71 
CASP9 PRELID1 UBA2 ZBTB37 FOSL2 ZNF704 Foxl2 
KCNQ1 CNN2 MMP14 SNX33 MLEC ANGEL2 SOX4 
FSCN1 ARPC5 ANXA2 RFFL PLEKHG2 FAM213B RBPJ 
KCNH2 FTL SNX30 MYPN PSMC4 ANGPT4 ALDOC 
TAGLN2 CERS2 SGMS2 CHMP3 ABHD18 ZEB1 SUPT16H 
LASP1 SEC61B PDLIM5 IBA57 PDE1A CTGF NGFR 
PNP PLEKHA3 PACS2 PSMG1 RBMXL1 LDLRAP1 KPNA6 
MSN EGFL7 BCL3 UGT2B10 RNF168 NR2C2 GSTP1 
EGFR VEGFA SESN2 SYAP1 C17orf64 RAB5C MEG3 
VKORC1 PIK3R2 EFHD2 CDK5R1 FBN1 ZNF394 AFTPH 
PRDM16 RGS3 EMID1 ATP13A3 NFAM1 HAPLN1 ERBB2 
TPM1 COL1A1 PRRT2 ZFP28 IGF1   
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Table S6: Gene targets of miR-93-3p from MirTarBase 
MYPOP ZNFX1 PDIK1L EXOC4 KIAA1671 UNC5C PPP1R13B 
SLC25A23 SLC35A4 MYCN PARP1 PFDN2 ARHGAP42 PAMR1 
HASPIN MTSS1L KMT2C RGPD5 QTRT2 ARID2 TIAM1 
ZC3H18 EIF4A1 BLCAP SC5D CCDC22 SELENOS DOCK5 
ENO2 H3F3B DCAF8 CENPF ADSL SV2B ACTN1 
SEL1L3 FAM98A AGO4 TOMM20 PSMD13 FOXH1 DHX9 
EEF1A1 UNC45A PLXNA4 HUWE1 DHX30 FAM174B MMP3 
CSAG1 RBM15B PDYN HEYL MAPRE1 VANGL1 CCDC127 
MCM3 USF1 ZNF790 TESK2 LRRC41 PIWIL2 CXCL5 
BAP1 FAR1 HRK CIT ACSL1 RAB34 NSUN4 
FKBP3 PDS5A SRCAP TCOF1 SUPT5H KANSL3 POTEG 
BMPR2 CDC42 TMEM59 ACTB LRBA NUP62 POTEM 
SMC1A SCRIB SNX9 TPD52L2 IRAK1 LRP3 SEC14L4 
RPL5 VARS ELAVL3 EPHB4 NCSTN TRIO STK35 
C1orf21 TEX261 SENP8 KLHDC3 ATIC PRPF8 GPRIN2 
NCAPD2 NUCKS1 KLF8 WNK1 SIN3A ARFGAP3 RTCB 
GANAB FAM193B CUL2 CTC1 EIF2AK1 TPRG1L EAF1 
INPP5D SUCLA2 ZNF573 CYCS NFKBIL1 NEMP1 ARHGAP31 
EIF4ENIF1 JMJD8 FER MAP2K1 CBR1 DNAJC5 LMBR1L 
GPR162 NCOA4 TRPM7 C1QBP UBE2R2 WASH3P EIF4EBP1 
SCN1A KIAA1147 PEAR1 THUMPD3 HACL1 WDR77 GPR89B 
SREBF1 CCNY MSH5 GCAT PARD3 IFT140 TUT1 
TULP3 HSPA5 HHAT NPM1 ABR GOT2 EIF1AD 
ACIN1 TAGLN2 MYO1F PPP1R12A ITPRIP TRIM28 SCAP 
NASP ACLY NCBP3 UTP14C PITRM1 STAT5B GPR89A 
AAGAB PUF60 KIAA0355 CNOT1 NUP160 RAB13 CANX 
FUK LRIG3 CRCP DHFR UBAP2L CASP2 SETD9 
FKBP5 DIDO1 TECPR2 MPP5 EEF1D ANAPC7 SMURF2 
AGO1 ELP1 PHLDA2 LRRC34 SURF4 FAM50A CCDC115 
LAMA4 MAFG GRIK3 HMMR SAMD4B MON1B CCDC86 
SUFU RABGAP1 DNAJC28 SERBP1 ARFGAP1 RRP12 FAM89B 
OTUB1 ANKRD27 SCN7A MYCBP FYN ARHGEF33 ADRM1 
UBA2 ZNF703 GPAT4 GLUD1 PLEKHG4 PTPN9 POMGNT1 
MCM7 HYOU1 SH2D5 HSP90AB1 ATP1A1 FDXACB1 CDC20 
ENAH DMTN SAMD4A TARDBP TMEM42 TLK2 MRPL49 
OXA1L PRRC2A YPEL1 SPTAN1 DAZAP1 FAM120A HNRNPUL1 
RUNDC3B SF3B2 NEUROD1 DMWD TMEM245 CCNG2 CTTNBP2NL 
ZNF44 EIF4H PDCD4 ATAD5 RNF4 NEDD4L ALS2 
KIAA1549L UBE2Q1 DAB2 
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Table S7: Gene targets of miR-205-5p from MirTarBase 
LRP1 SMIM13 NDUFA4 C6orf201 UBE2Z VPS52 PTPRM 
ZEB1 SERINC3 MMD NUDT21 GNAS TMEM239 AR 
DDX5 RNF217 MGLL KLHL5 SQLE SLC7A2 SMAD4 
INPPL1 NFAT5 MED13 NCAPG CPEB3 SLC41A1 BCL6 
MED1 LCOR MARCKS LMNA ETF1 RBBP4 ACSL4 
E2F5 NPRL3 LYSMD3 RUNX2 ZNF585B PAIP2B ITGA5 
E2F1 ACTRT3 LYN HMGB1 HMGB3 NOX5 ACSL1 
ERBB3 GOT1 LRRC59 PRDX2 PTEN NEK9 STK38L 
ZEB2 F2RL2 LPCAT1 SMAD2 ESRRG MRPL44 NUFIP2 
PRKCE DHCR24 IPO7 UVRAG PHLPP2 SLC25A25 PTPRJ 
VEGFA EID2B SARAF CENPF KCNJ10 CREB1 XPR1 
SIGMAR1 SLC38A1 EZR SATB2 YEATS2 CDK1 ETNK1 
IL24 RAB11FIP
1 
ENPP4 CCNJ VAMP1 RAN DMXL2 
IL32 C11orf74 CUL5 HSPA8 TOLLIP BAMBI NSF 





TMEM123 TMSB4X HOXA11 
CYR61 SLC39A14 CDK6 ABCF1 TAF11 GM2A IMPAD1 
CTGF BDP1 GUCD1 ZSWIM5 SERTAD2 TMEM201 TCF20 
ERBB2 TRAF3IP1 C1orf123 CFAP65 RTN3 PHF8 PRR15 
LAMC1 ICK B4GALT6 PRRG4 RFX7 TM9SF2 MDH2 
LRRK2 PRLR B4GALT5 BCL9L RAP2B YWHAH KCTD20 
YES1 BORCS5 AFF4 SHISA6 PLAGL2 SPDL1 XPOT 
SRD5A1 ACP1 AFF1 JMJD1C PICALM MAPK14 SLC5A12 
SRC PHF12 TEX35 SMNDC1 PHC2 TXNL1 VTI1A 
BCL2 MAP3K9 NOTCH2 PLCXD2 PARD6B RGS6 YY1 
SMAD1 MAML2 NIPA2 ANGPTL7 PANK1 TNFSF8 NDUFB2 
 
 
